U.S. patent application number 12/115171 was filed with the patent office on 2008-09-04 for thienopyrimidinediones and their use in the modulation of autoimmune disease.
Invention is credited to Simon David Guile.
Application Number | 20080214579 12/115171 |
Document ID | / |
Family ID | 20290154 |
Filed Date | 2008-09-04 |
United States Patent
Application |
20080214579 |
Kind Code |
A1 |
Guile; Simon David |
September 4, 2008 |
THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF
AUTOIMMUNE DISEASE
Abstract
The invention relates to thienopyrimidinediones of formula (1):
##STR00001## in which R.sup.1, R.sup.2, R.sup.3, Q, and Ar are
defined in the specification. The invention also relates to
processes for the preparation of the compounds of formula (1),
pharmaceutical compositions containing these compounds, and use of
these compounds in therapy, in particular in immunosuppression
therapy.
Inventors: |
Guile; Simon David;
(Loughborough, GB) |
Correspondence
Address: |
FISH & RICHARDSON P.C.
P.O BOX 1022
MINNEAPOLIS
MN
55440-1022
US
|
Family ID: |
20290154 |
Appl. No.: |
12/115171 |
Filed: |
May 5, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10542197 |
Jul 14, 2005 |
7384951 |
|
|
PCT/SE2004/000052 |
Jan 15, 2004 |
|
|
|
12115171 |
|
|
|
|
Current U.S.
Class: |
514/260.1 |
Current CPC
Class: |
A61P 11/06 20180101;
A61P 37/02 20180101; A61P 35/00 20180101; A61P 37/06 20180101; A61P
37/00 20180101; A61P 29/00 20180101; C07D 495/04 20130101 |
Class at
Publication: |
514/260.1 |
International
Class: |
A61K 31/519 20060101
A61K031/519; A61P 35/00 20060101 A61P035/00; A61P 37/00 20060101
A61P037/00; A61P 37/06 20060101 A61P037/06 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 17, 2003 |
SE |
0300119-5 |
Claims
1. A method of inhibiting the proliferation of T cells, comprising
administering to a patient a therapeutically effective amount of a
compound of formula (1): ##STR00050## wherein R.sub.1 and R.sub.2
each independently represent a C.sub.1-6alkyl, C.sub.3-6alkenyl,
C.sub.3-5cycloalkylC.sub.1-3alkyl or C.sub.3-6cycloalkyl; each of
which is optionally substituted by 1 to 3 halogen atoms; R.sub.3 is
a group CO-G or SO.sub.2-G, where G is a 5- or 6-membered ring
containing a nitrogen atom and a second heteroatom selected from
the group consisting of oxygen and sulphur adjacent to the
nitrogen; the ring being substituted by at least one group selected
from the group consisting of halogen or C.sub.1-4 alkyl optionally
substituted by up to five halogen atoms, and optionally substituted
by up to a further 4 groups independently selected from the group
consisting of halogen, hydroxyl, and C.sub.1-4 alkyl optionally
substituted by up to five halogen atoms; Q is CR.sup.4R.sup.5 ,
where R.sup.4 is hydrogen, fluorine or C.sup.1-6 alkyl and R.sup.5
is hydrogen, fluorine or hydroxy; Ar is a 5- to 10-membered
aromatic ring system in which up to 4 ring atoms are heteroatoms
independently selected from the group consisting of nitrogen,
oxygen and sulphur, the ring system being optionally substituted by
one or more substituents independently selected from the group
consisting of C.sub.1-4alkyl optionally substituted by 1, 2 or 3
hydroxy groups, C.sub.1-4alkoxy, halogen, haloalkyl, dihaloalkyl,
trihaloalkyl, C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4 alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, -N(R.sup.6)R.sup.7 , -(CH.sub.2)pN(R.sup.8)R.sup.9 ,
hydroxy, C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl,
carbonyl, C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl,
carboxy, and SO.sub.2N(R.sup.6)R.sup.7; or Ar is optionally
substituted by a 5 or 6 membered aromatic ring containing up to 4
heteroatoms independently selected from the group consisting of
nitrogen, oxygen and sulphur; the 5 or 6 membered aromatic ring
being optionally substituted by one or more substituents
independently selected from the group consisting from
C.sub.1-4alkyl optionally substituted by 1, 2 or 3 hydroxy groups,
C.sub.4alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl,
C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano,- N(R.sup.6)R.sup.7, -(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4 alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2N(R.sup.6)R.sup.7; p is 1,2,3or4; R.sup.6 and R.sup.7 each
independently represent a hydrogen atom, C.sub.1-4alkanoyl or
C.sub.1-4alkyl, or together with the nitrogen atom to which they
are attached form a 5- to 7-membered saturated heterocyclic ring;
and R.sup.8 and R.sup.9 each independently represent a hydrogen
atom, C.sub.1-4alkanoyl or C.sub.1-4alkyl, or together with the
nitrogen atom to which they are attached form a 5- to 7-membered
saturated heterocyclic ring; or pharmaceutically acceptable salts
thereof.
2. The method of claim 1, wherein R.sup.1 is ethyl, propyl, butyl
or cyclopropyl.
3. The method of claim 1, wherein R.sup.2 is methyl.
4. The method of claim 1, wherein R.sup.3 a group CO-G.
5. The method of claim 1, wherein Q is CH.sub.2.
6. The method of claim 1, wherein Ar is a 5-membered aromatic ring
containing two heteroatoms optionally substituted as defined in
claim 1 or Ar is a 9- or 10- membered bicyclic ring containing one,
two or three heteroatoms and optionally substituted as defined in
claim 1, or phenyl, optionally substituted as defined in claim
1.
7. The method of claim 6, wherein Ar is a thienyl, pyrazole or
thiazole ring each substituted by two or three C.sub.1-4alkyl,
halogen, trifluoromethyl substituents and/or also substituted by a
2-pyrimidinyl or 2-pyridyl group.
8. The method of claim 6, wherein Ar is a group of sub-formula (i):
##STR00051## in which R.sup.10 and R.sup.11 are independently H,
C.sub.4alkyl, or haloC.sub.1-6alkyl and R.sub.12 is H,
C.sub.1-6alkyl, haloC.sub.1-6alkyl, or a 5- to 6-membered aromatic
ring system in which up to 3 ring atoms are heteroatoms
independently selected from the group consisting of oxygen, sulphur
and nitrogen, which ring are optionally substituted by one or more
substituents independently selected from the group consisting of
C.sub.1-4alkyl optionally substituted by 1, 2 or 3 hydroxy groups,
C.sub.1-4alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl,
C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl, nitro, cyano,
-N(R.sup.6)R.sup.7, -(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2N(R.sup.6)R.sup.7, in which R.sup.6, R.sup.7, R.sup.8,
R.sup.9 and p are as defined in claim 1.
9. The method of claim 8, wherein R.sup.10 and R.sup.11 are
methyl.
10. The method of claim 9, wherein R.sup.12 is H, C.sub.1-3alkyl or
a 5- to 6- membered aromatic ring system in which up to 3 ring
atoms are optionally heteroatoms independently selected from the
group consisting of oxygen, sulphur and nitrogen, the ring system
being optionally substituted by hydroxyl.
11. The method of claim 1, wherein the compound of formula (1) is
selected from the group consisting of: (S)-2-[[6-[(3,5-Dimethyl-
1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-
methylpropyl)-2,4-dioxo-thieno
[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxazolidinol,
(S)-2-[[6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-met-
hyl-1-(2-
methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-m-
ethyl-4-isoxazolidinol, 1-Cyclopropyl-6-[(3,5-dimethyl-
1H-pyrazol-4-yl)methyl]-5- [[(4S)-4-hydroxy-4-methyl-
2-isoxazolidinyl]carbonyl]-3-methyl-thieno[2,3-d]pyrimidine-2,4(1H,3H)-di-
one,
(S)-2-[[6-[(1H-1,2,3-Benzotriazol-1-yl)methyl]-1,2,3,4-tetrahydro-3-m-
ethyl-1-(1-
methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-i-
soxazolidinol, (S)-2-[[6-
[(4,5-Dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,4-tetrahydro-1-eth-
yl-
3-methyl-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-is-
oxazolidinol,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(2-meth-
ylpropyl)-6-
(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)--
dione,
(4S)-4-methyl-2-[[1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-6--
(4-
quinolinylmethyl)thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-isoxazolidino-
l,
(4S)-2-[[6-[(2,4-Dichloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-3-meth-
yl-1-(2-
methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-m-
ethyl-4-isoxazolidinol, (4S)-2-[[6-
[(3-Bromo-2-thienyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-methylpropyl-
)-
2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxazolidin-
ol,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-m-
ethylethyl)-6-
[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,3-d]pyrim-
idine-2,4(1H,3H)- dione,
6-[[3,5-Dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-5-[[(4S)-4-hydro-
xy-4-methyl-
2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimid-
ine-2,4-(1H,3H)- dione,
5-[[(4S)-4-Hydroxy-4-methyl-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methyl-
ethyl)-6-
(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thieno[2,3-d]pyrimidine-2,-
4(1H,3H)-dione,
(4S)-2-[[6-[[3,5-Dimethyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-
-tetrahydro-3- methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]
pyrimidin-5-yl] carbonyl]-4-methyl-4- isoxazolidinol,
(4S)-2-[[6-[[3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]
methyl]-1,2,3,4-tetrahydro-
3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d] pyrimidin-5-yl]
carbonyl]-4-methyl-4- isoxazolidinol,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]
carbonyl]-3-methyl-1-(1-methylethyl)-6-
[(1-phenyl-1H-pyrazol-4-yl)methyl]-thieno[2,3-d]
pyrimidine-2,4-(1H,3H)-dione, 6-[(8-Fluoroquinolin-4-yl)methyl]-5-
{[(4S)-4-hydroxy-4-methylisoxazolidin-2- yl]
carbonyl}-1-isopropyl-3-methylthieno[2,3-d]
pyrimidine-2,4(1H,3H)-dione,
5-{[(4S)-4-Hydroxy-4-methylisoxazolidin-2-yl]
carbonyl}-1-isopropyl-3-methyl-6-(4-
pyrimidin-2-ylbenzyl)thieno[2,3-d] pyrimidine-2,4(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]
carbonyl]-3-methyl-1-(1-methylethyl)-6- [(5
-(2-pyridinyl)-2-thienyl)methyl]-thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dion-
e, 6-[(1,3-Dimethyl-1H-5-pyrazolyl)methyl]-5-
]](4S)-4-hydroxy-4-methyl-2-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-thieno[2,3-d]pyrimidi-
ne-2,4-(1H,3H)- dione,
6-[(3,5-Dimethyl-4-isothiozolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidin-
e-2,4-(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[[1-(2-thiazolyl)-1H-pyrazol-4-yl]methyl]thieno[2,3-d]pyrimidine-2,4-(1H,-
3H)-dione,
6-[(4-Fluorophenyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-isoxaz-
olidinyl]carbonyl]-3-
methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
(1H-1,2,3-triazol-1-ylmethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
6-[(6-Chloroimidazo[1,2-a]pyridin-3-yl)methyl]-5-[[(4S)-4-hydroxy-4-methy-
l-2-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrim-
idine-2,4-(1H,3H)-dione,
5-[[(4S)-4-hydroxy-4-methylisoxazolidin-2-yl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[[4-(2-pyridinyl)phenyl]methyl]-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione,
(4S)-4-Methyl-2-[[1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-6-[[5-met-
hyl-1-(2-
pyrimidinyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,4-dio-
xothieno[2,3-d]pyrimidin-5- yl]carbonyl]-4-isoxazolidinol, (4S)-2-
[[6- [[3,5-Dimethyl- 1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-
1,2,3,4-tetrahydro-
3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-5
-yl]carbonyl]-4-ethyl-4- isoxazolidinol, (4S)-2-
[[6-[[1-(2,3-Dihydro-2-oxo-4-pyrimidinyl)-3,5-dimethyl-1H-pyrazol-4-
yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[-
2,3-d]pyrimidin-5- yl]carbonyl]-4-methyl-4-isoxazolidinol, 5-
[[(4R)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methyl-
ethyl)-6-
[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,-
3-d]pyrimidine-2,4(1H,3H)- dione, and pharmaceutically acceptable
salts thereof.
12. A method of effecting immunosuppression, comprising
administering to a patient a therapeutically effective amount of a
compound of formula (1): ##STR00052## wherein R.sup.1 and R.sup.2
each independently represent a C.sub.1-6alkyl, C.sub.3-6alkenyl,
C.sub.3-5cycloalkylC.sub.1-3alkyl or C.sub.36cycloalkyl; each of
which is optionally substituted by 1 to 3 halogen atoms; R.sup.3 is
a group CO-G or SO.sub.2-G, where G is a 5- or 6-membered ring
containing a nitrogen atom and a second heteroatom selected from
the group consisting of oxygen and sulphur adjacent to the
nitrogen; the ring being substituted by at least one group selected
from the group consisting of halogen or C.sub.1-4 alkyl optionally
substituted by up to five halogen atoms, and optionally substituted
by up to a further 4 groups independently selected from the group
consisting of halogen, hydroxyl, and C.sub.1-4 alkyl optionally
substituted by up to five halogen atoms; Q is CR.sup.4R.sup.5,
where R.sup.4 is hydrogen, fluorine or C.sup.1-6 alkyl and R.sup.5
is hydrogen, fluorine or hydroxy; Ar is a 5- to 10-membered
aromatic ring system in which up to 4 ring atoms are heteroatoms
independently selected from the group consisting of nitrogen,
oxygen and sulphur, the ring system being optionally substituted by
one or more substituents independently selected from the group
consisting of C.sub.1-4alkyl optionally substituted by 1, 2 or 3
hydroxy groups, C.sub.1-4 alkoxy, halogen, haloalkyl, dihaloalkyl,
trihaloalkyl, C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4 alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, -N(R.sup.6)R.sup.7, -(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2N(R.sup.6)R.sup.7; or Ar is optionally substituted by a 5
or 6 membered aromatic ring containing up to 4 heteroatoms
independently selected from the group consisting of nitrogen,
oxygen and sulphur; the 5 or 6 membered aromatic ring being
optionally substituted by one or more substituents independently
selected from the group consisting from C.sub.1-4alkyl optionally
substituted by 1,2 or 3 hydroxy groups, C.sub.1-4alkoxy, halogen,
haloalkyl, dihaloalkyl, trihaloalkyl,
C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, - N(R.sup.6)R.sup.7, -(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4 alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2N(R.sup.6)R.sup.7 p is 1,2,3or4; R.sup.6 and R.sup.7 each
independently represent a hydrogen atom, C.sub.1-4alkanoyl or
C.sub.1-4alkyl, or together with the nitrogen atom to which they
are attached form a 5- to 7-membered saturated heterocyclic ring;
and R.sup.8 and R.sup.9 each independently represent a hydrogen
atom, C.sub.1-4alkanoyl or C.sub.1-4alkyl, or together with the
nitrogen atom to which they are attached form a 5- to 7-membered
saturated heterocyclic ring; or pharmaceutically acceptable salts
thereof.
13. The method of claim 12, wherein R.sup.1 is ethyl, propyl, butyl
or cyclopropyl.
14. The method of claim 12, wherein R.sup.2 is methyl.
15. The method of claim 12, wherein R.sup.3 is a group CO-G.
16. The method of claim 12, wherein Q is CH.sub.2.
17. The method of claim 12, wherein Ar is a 5-membered aromatic
ring containing two heteroatoms optionally substituted as defined
in claim 1 or Ar is a 9- or 10- membered bicyclic ring containing
one, two or three heteroatoms and optionally substituted as defined
in claim 1, or phenyl, optionally substituted as defined in claim
1.
18. The method of claim 17, wherein Ar is a thienyl, pyrazole or
thiazole ring each substituted by two or three C.sub.1-4alkyl,
halogen, trifluoromethyl substituents and/or also substituted by a
2-pyrimidinyl or 2-pyridyl group.
19. The method of claim 17, wherein Ar is a group of sub-formula
(i): ##STR00053## in which R.sup.10 and R.sup.11 are independently
H, C.sub.1-4alkyl, or haloC.sub.1-6alkyl and R.sup.12 is
H,C.sub.1-6alkyl, haloC.sub.1-6alkyl, or a 5- to 6-membered
aromatic ring system in which up to 3 ring atoms are heteroatoms
independently selected from the group consisting of oxygen, sulphur
and nitrogen, which ring are optionally substituted by one or more
substituents independently selected from the group consisting of
C.sub.1-4alkyl optionally substituted by 1,2 or 3 hydroxy groups,
C.sub.1-4alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl,
C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio, C.sub.1-4
alkoxycarbonyl, C.sub.24alkanoyl, oxo, thioxo, nitro, cyano,
-N(R.sup.6)R.sup.7, (CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2 N(R.sup.6)R.sup.7, in which R.sup.6, R.sup.7, R.sup.8,
R.sup.9 and p are as defined in claim 1.
20. The method of claim 19, wherein R.sup.10 and R.sup.11 are
methyl.
21. The method of claim 20, wherein R.sup.12 is H, C.sub.1-3alkyl
or a 5- to 6- membered aromatic ring system in which up to 3 ring
atoms are optionally heteroatoms independently selected from the
group consisting of oxygen, sulphur and nitrogen, the ring system
being optionally substituted by hydroxyl.
22. The method of claim 12, wherein the compound of formula (1) is
selected from the group consisting of: (S)-2-[[6-[(3,5-Dimethyl-
1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-
methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5
-yl]carbonyl]-4-methyl-4-isoxazolidinol, (S)-2-[[6-[(3,5-Dimethyl-
1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-
methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-i-
soxazolidinol, 1-Cyclopropyl-6-[(3,5
-dimethyl-1H-pyrazol-4-yl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-
2-isoxazolidinyl]carbonyl]-3-methyl-thieno[2,3-d]pyrimidine-2,4(1H,3H)-di-
one,
(S)-2-[[6-](1H-1,2,3-Benzotriazol-1-yl)methyl]-1,2,3,4-tetrahydro-3-m-
ethyl-1-(1-
methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-i-
soxazolidinol, (S)-2-[[6- [(4,5-Dichloro-2-methyl-1H-imidazol-
1-yl)methyl]-1,2,3,4-tetrahydro- 1-ethyl-
3-methyl-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxa-
zolidinol,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-
-1-(2-methylpropyl)-6-
(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)--
dione,
(4S)-4-methyl-2-[[1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-6--
(4-
quinolinylmethyl)thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-isoxazolidino-
l,
(4S)-2-[[6-[(2,4-Dichloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-3-meth-
yl-1-(2-
methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-m-
ethyl-4-isoxazolidinol,
(4S)-2-[[6-[(3-Bromo-2-thienyl)methyl]-1,2,3,4-tetrahydro-3-methyl-
1-(2-methylpropyl)-
2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxazolidinol-
,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-met-
hylethyl)-6- [[5-methyl-3-(trifluoromethyl)-
1H-pyrazol-4-yl]methyl]-thieno[2,3-d]pyrimidine-2,4(1H,3H)- dione,
6- [[3,5-Dimethyl- 1-(2-pyridinyl)- 1H-pyrazol-4-yl]methyl]-5-
[[(4S)-4-hydroxy-4-methyl-
2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimid-
ine-2,4-(1H,3H)- dione,
5-[[(4S)-4-Hydroxy-4-methyl-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methyl-
ethyl)-6-
(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thieno[2,3-d]pyrimidine-2,-
4(1H,3H)-dione, (4S)-2-[[6-
[[3,5-Dimethyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-
-3-
methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbony-
l]-4-methyl-4- isoxazolidinol, (4S)-2-[[6- [[3,5-Dimethyl-
1-(2-pyrimidinyl)- 1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-
3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl-
]-4-methyl-4- isoxazolidinol, 5-
[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methyl-
ethyl)-6-
[(1-phenyl-1H-pyrazol-4-yl)methyl]-thieno[2,3-d]pyrimidine-2,4-(-
1H,3H)-dione,
6-[(8-Fluoroquinolin-4-yl)methyl]-5-{[(4S)-4-hydroxy-4-methylisoxazolidin-
-2-
yl]carbonyl}-1-1-isopropyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)--
dione,
5-{[(4S)-4-Hydroxy-4-methylisoxazolidin-2-yl]carbonyl}-1-1-isopropy-
l-3-methyl-6-(4- pyrimidin-2-ylbenzyl)thieno
[2,3-d]pyrimidine-2,4(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[(5-(2-pyridinyl)-2-thienyl)methyl]-thieno[2,3-d]pyrimidine-2,4-(1H,3H)-d-
ione, 6-[(1,3-Dimethyl-1H-5-pyrazolyl)methyl]-5-
[[(4S)-4-hydroxy-4-methyl-2-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-thieno[2,3-d]pyrimidi-
ne-2,4-(1H,3H)- dione,
6-[(3,5-Dimethyl-4-isothiozolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno
[2,3-d]pyrimidine-2,4-(1H,3H)-dione, 5-
[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methyl-
ethyl)-6- [[1-(2-thiazolyl)-1H-pyrazol-4-yl]methyl]thieno
[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
6-[(4-Fluorophenyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]c-
arbonyl]-3- methyl-1-(1-methylethyl)thieno
[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6- (1H-1,2,3-triazol-1-ylmethyl)thieno
[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
6-[(6-Chloroimidazo[1,2-a]pyridin-3-yl)methyl]-5-[[(4S)-4-hydroxy-4-methy-
l-2- isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno
[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
5-[[(4S)-4-hydroxy-4-methylisoxazolidin-2-yl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6- [[-(2-pyridinyl)phenyl]methyl]-thieno
[2,3-d]pyrimidine-2,4(1H,3H)-dione, (4S)-4-Methyl-2-
[[1,2,3,4-tetrahydro-3-methyl-1-( 1-methylethyl)-6-
[[5-methyl-1-(2-
pyrimidinyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,4-dioxothieno[-
2,3-d]pyrimidin-5- yl]carbonyl]-4-isoxazolidinol, (4S)-2-[[6-
]]3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-
1,2,3,4-tetrahydro- 3-methyl-1-(1-methylethyl)-2,4-dioxothieno
[2,3-d]pyrimidin-5-yl]carbonyl]-4-ethyl-4- isoxazolidinol, (4S)-2-
[[6-[[1-(2,3-Dihydro-2-oxo-4-pyrimidinyl)-3,5-dimethyl-
1H-pyrazol-4- yl]methyl]-
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno
[2,3-d]pyrimidin-5- yl]carbonyl]-4-methyl-4-isoxazolidinol,
5-[[(4R)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno
[2,3-d]pyrimidine-2,4(1H,3H)- dione, and pharmaceutically
acceptable salts thereof.
23. A method of treating a reversible obstructive airways disease
in a patient suffering from the disease, comprising administering
to the patient a therapeutically effective amount of a compound of
formula (1): ##STR00054## wherein R.sup.1 and R.sup.2 each
independently represent a C.sub.1-6alkyl, C.sub.3-6alkenyl,
C.sub.3-5cycloalkylC.sub.1-3alkyl or C.sub.3-6cycloalkyl; each of
which is optionally substituted by 1 to 3 halogen atoms; R.sup.3 is
a group CO-G or SO.sub.2-G, where G is a 5- or 6-membered ring
containing a nitrogen atom and a second heteroatom selected from
the group consisting of oxygen and sulphur adjacent to the
nitrogen; the ring being substituted by at least one group selected
from the group consisting of halogen or C.sub.1-4 alkyl optionally
substituted by up to five halogen atoms, and optionally substituted
by up to a further 4 groups independently selected from the group
consisting of halogen, hydroxyl, and C.sub.1-4 alkyl optionally
substituted by up to five halogen atoms; Q is CR.sup.4R.sup.5,
where R.sup.4 is hydrogen, fluorine or C.sub.1-6 alkyl and R.sup.5
is hydrogen, fluorine or hydroxy; Ar is a 5- to 10-membered
aromatic ring system in which up to 4 ring atoms are heteroatoms
independently selected from the group consisting of nitrogen,
oxygen and sulphur, the ring system being optionally substituted by
one or more substituents independently selected from the group
consisting of C.sub.1-4alkyl optionally substituted by 1, 2 or 3
hydroxy groups, C.sub.1-4 alkoxy, halogen, haloalkyl, dihaloalkyl,
trihaloalkyl, C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4 alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, -N(R.sup.6)R.sup.7, -(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2N(R.sub.6)R.sub.7; or Ar is optionally substituted by a 5
or 6 membered aromatic ring containing up to 4 heteroatoms
independently selected from the group consisting of nitrogen,
oxygen and sulphur; the 5 or 6 membered aromatic ring being
optionally substituted by one or more substituents independently
selected from the group consisting from C.sub.1-4alkyl optionally
substituted by 1, 2 or 3 hydroxy groups, C.sub.1-4alkoxy, halogen,
haloalkyl, dihaloalkyl, trihaloalkyl,
C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, - N(R.sup.6)R.sup.7, -(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2N(R.sup.6)R.sup.7; p is 1,2,3or4; R.sup.6 and R.sup.7 each
independently represent a hydrogen atom, C.sub.1-4alkanoyl or
C.sub.1-4alkyl, or together with the nitrogen atom to which they
are attached form a 5- to 7-membered saturated heterocyclic ring;
and R.sup.8 and R.sup.9 each independently represent a hydrogen
atom, C.sub.1-4alkanoyl or C.sub.1-4alkyl, or together with the
nitrogen atom to which they are attached form a 5- to 7-membered
saturated heterocyclic ring; and pharmaceutically acceptable salts
thereof.
24. The method of claim 23, wherein the obstructive airways disease
is chronic obstructive pulmonary disease.
25. The method of claim 23, wherein R.sup.1 is ethyl, propyl, butyl
or cyclopropyl.
26. The method of claim 23, wherein R.sup.2 is methyl.
27. The method of claim 23, wherein R.sup.3 is a group CO-G.
28. The method of claim 23, wherein Q is CH.sub.2.
29. The method of claim 23, wherein Ar is a 5-membered aromatic
ring containing two heteroatoms optionally substituted as defined
in claim 1 or Ar is a 9- or 10- membered bicyclic ring containing
one, two or three heteroatoms and optionally substituted as defined
in claim 1, or phenyl, optionally substituted as defined in claim
1.
30. The method of claim 29, wherein Ar is a thienyl, pyrazole or
thiazole ring each substituted by two or three C.sub.1-4alkyl,
halogen, trifluoromethyl substituents and/or also substituted by a
2-pyrimidinyl or 2-pyridyl group.
31. The method of claim 29, wherein Ar is a group of sub-formula
(i): ##STR00055## in which R.sup.10 and R.sup.11 are independently
H, C.sub.1-4alkyl, or haloC.sub.1-6alkyl and R.sup.12 is H,
C.sub.1-6alkyl, haloC.sub.1-6alkyl, or a 5- to 6-membered aromatic
ring system in which up to 3 ring atoms are heteroatoms
independently selected from the group consisting of oxygen, sulphur
and nitrogen, which ring are optionally substituted by one or more
substituents independently selected from the group consisting of
C.sub.1-4alkyl optionally substituted by 1, 2 or 3 hydroxy groups,
C.sub.1-4alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl,
C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, -N(R.sup.6)R.sup.7,-(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2 N(R.sup.6)R.sup.7, in which R.sup.6, R.sup.7, R.sup.8,
R.sup.9 and p are as defined in claim 1.
32. The method of claim 31, wherein R.sup.10 and R.sup.11 are
methyl.
33. The method of claim 32, wherein R.sup.12 is H, C.sub.1-3alkyl
or a 5- to 6- membered aromatic ring system in which up to 3 ring
atoms are optionally heteroatoms independently selected from the
group consisting of oxygen, sulphur and nitrogen, the ring system
being optionally substituted by hydroxyl.
34. The method of claim 23, wherein the compound of formula (1) is
selected from the group consisting of: (S)-2-[[6-[(3,5-Dimethyl-
1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-
methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5
-yl]carbonyl]-4-methyl-4-isoxazolidinol,
(S)-2-[[6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-met-
hyl-1-(2-
methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-m-
ethyl-4-isoxazolidinol,
1-Cyclopropyl-6-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-5-[[(4S)-4-hydroxy-
-4-methyl-
2-isoxazolidinyl]carbonyl]-3-methyl-thieno[2,3-d]pyrimidine-2,4-
(1H,3H)-dione, (S)-2-[[6-](1H- 1,2,3-Benzotriazol-
1-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-
methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-i-
soxazolidinol,
(S)-2-[[6-](4,5-Dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,4-tetrah-
ydro-1-ethyl-
3-methyl-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxa-
zolidinol,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-
-1-(2-methylpropyl)-6-
(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)--
dione,
(4S)-4-methyl-2-[[1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-6--
(4-
quinolinylmethyl)thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-isoxazolidino-
l,
(4S)-2-[[6-[(2,4-Dichloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-3-meth-
yl-1-(2-
methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-m-
ethyl-4-isoxazolidinol,
(4S)-2-[[6-[(3-Bromo-2-thienyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-m-
ethylpropyl)-
2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxazolidinol-
,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-met-
hylethyl)-6-
[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,3-d]pyrim-
idine-2,4(1H,3H)- dione,
6-[[3,5-Dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-5-[[(4S)-4-hydro-
xy-4-methyl-
2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimid-
ine-2,4-(1H,3H)- dione,
5-[[(4S)-4-Hydroxy-4-methyl-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methyl-
ethyl)-6-
(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thieno[2,3-d]pyrimidine-2,-
4(1H,3H)-dione,
(4S)-2-[[6-[[3,5-Dimethyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-
-tetrahydro-3-
methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]--
4-methyl-4- isoxazolidinol,
(4S)-2-[[6-[[3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-
1,2,3 ,4-tetrahydro-
3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl-
]-4-methyl-4- isoxazolidinol,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[(1-phenyl-1H-pyrazol-4-yl)methyl]-thieno[2,3-d]pyrimidine-2,4-(1H,3H)-di-
one,
6-[(8-Fluoroquinolin-4-yl)methyl]-5-{[(4S)-4-hydroxy-4-methylisoxazol-
idin-2-
yl]carbonyl}-1-1-isopropyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,-
3H)-dione,
5-{[(4S)-4-Hydroxy-4-methylisoxazolidin-2-yl]carbonyl}-1-1-isop-
ropyl-3-methyl-6-(4-
pyrimidin-2-ylbenzyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[(5-(2-pyridinyl)-2-thienyl)methyl]-thieno[2,3-d]pyrimidine-2,4-(1H,3H)-d-
ione,
6-[(1,3-Dimethyl-1H-5-pyrazolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl--
2-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-thieno[2,3-d]pyrimi-
dine-2,4-(1H,3H)- dione,
6-[(3,5-Dimethyl-4-isothiozolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidin-
e-2,4-(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6- [[1-(2-thiazolyl)-
1H-pyrazol-4-yl]methyl]thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
6-[(4-Fluorophenyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]c-
arbonyl]-3-
methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
(1H-1,2,3-triazol-1-ylmethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
6-[(6-Chloroimidazo]1,2-a]pyridin-3-yl)methyl]-5-[[(4S)-4-hydroxy-4-methy-
l-2-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrim-
idine-2,4-(1H,3H)-dione,
5-[[(4S)-4-hydroxy-4-methylisoxazolidin-2-yl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[[4-(2-pyridinyl)phenyl]methyl]-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione,
(4S)-4-Methyl-2-[[1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-6-[[5-met-
hyl-1-(2-
pyrimidinyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,4-dio-
xothieno[2,3-d]pyrimidin-5 - yl]carbonyl]- 4-isoxazolidinol,
(4S)-2-[[6-[[3,5-Dimethyl-
1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-
3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-
-4-ethyl-4- isoxazolidinol,
(4S)-2-[[6-[[1-(2,3-Dihydro-2-oxo-4-pyrimidinyl)-3,5-dimethyl-
1H-pyrazol-4- yl]methyl]-
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrim-
idin-5- yl]carbonyl]-4-methyl-4-isoxazolidinol,
5-[[(4R)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,3-d]pyrim-
idine-2,4(1H,3H)- dione, and pharmaceutically acceptable salts
thereof.
35. A method of treating cancer in a patient suffering from the
cancer, comprising administering to a patient a therapeutically
effective amount of a compound of formula (1): ##STR00056## wherein
R.sup.1 and R.sup.2 each independently represent a C.sub.1-6alkyl,
C.sub.3-6alkenyl, C.sub.3-5cycloalkylC.sub.1-3alkyl or
C.sub.3-6cycloalkyl; each of which is optionally substituted by 1
to 3 halogen atoms; R.sup.3 is a group CO-G or SO.sub.2-G, where G
is a 5- or 6-membered ring containing a nitrogen atom and a second
heteroatom selected from the group consisting of oxygen and sulphur
adjacent to the nitrogen; the ring being substituted by at least
one group selected from the group consisting of halogen or C.sub.4
alkyl optionally substituted by up to five halogen atoms, and
optionally substituted by up to a further 4 groups independently
selected from the group consisting of halogen, hydroxyl, and
C.sub.1-4 alkyl optionally substituted by up to five halogen atoms;
Q is CR.sup.4R.sup.5, where R.sup.4 is hydrogen, fluorine or
C.sub.1-6 alkyl and R.sup.5 is hydrogen, fluorine or hydroxy; Ar is
a 5- to 10-membered aromatic ring system in which up to 4 ring
atoms are heteroatoms independently selected from the group
consisting of nitrogen, oxygen and sulphur, the ring system being
optionally substituted by one or more substituents independently
selected from the group consisting of C.sub.1-4alkyl optionally
substituted by 1, 2 or 3 hydroxy groups, C.sub.1-4alkoxy, halogen,
haloalkyl, dihaloalkyl, trihaloalkyl,
C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, -N(R.sup.6)R.sup.7, -(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2N(R.sup.6)R.sup.7; or Ar is optionally substituted by a 5
or 6 membered aromatic ring containing up to 4 heteroatoms
independently selected from the group consisting of nitrogen,
oxygen and sulphur; the 5 or 6 membered aromatic ring being
optionally substituted by one or more substituents independently
selected from the group consisting from C.sub.1-4alkyl optionally
substituted by 1,2 or 3 hydroxy groups, C.sub.1-4alkoxy, halogen,
haloalkyl, dihaloalkyl, trihaloalkyl,
C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, - N(R.sup.6)R.sup.7, -(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2N(R.sup.6)R.sup.7; p is 1,2,3or4; R.sup.6 and R.sup.7 each
independently represent a hydrogen atom, C.sub.1-4alkanoyl or
C.sub.1-4alkyl, or together with the nitrogen atom to which they
are attached form a 5- to 7-membered saturated heterocyclic ring;
and R.sup.8 and R.sup.9 each independently represent a hydrogen
atom, C.sub.1-4alkanoyl or C.sub.1-4alkyl, or together with the
nitrogen atom to which they are attached form a 5- to 7-membered
saturated heterocyclic ring; or pharmaceutically acceptable salts
thereof.
36. The method of claim 35, wherein R.sup.1 is ethyl, propyl, butyl
or cyclopropyl.
37. The method of claim 35, wherein R.sup.2 is methyl.
38. The method of claim 35, wherein R.sup.3 is a group CO-G.
39. The method of claim 35, wherein Q is CH.sub.2.
40. The method of claim 35, wherein Ar is a 5-membered aromatic
ring containing two heteroatoms optionally substituted as defined
in claim 1 or Ar is a 9- or 10- membered bicyclic ring containing
one, two or three heteroatoms and optionally substituted as defined
in claim 1, or phenyl, optionally substituted as defined in claim
1.
41. The method of claim 35, wherein Ar is a thienyl, pyrazole or
thiazole ring each substituted by two or three C.sub.1-4alkyl,
halogen, trifluoromethyl substituents and/or also substituted by a
2-pyrimidinyl or 2-pyridyl group.
42. The method of claim 35, wherein Ar is a group of sub-formula
(i): ##STR00057## in which R.sup.10 and R.sup.11 are independently
H, C.sub.1-4alkyl, or haloC.sub.1-6alkyl and R.sup.12 is H,
C.sub.1-6alkyl, haloC.sub.1-6alkyl, or a 5- to 6-membered aromatic
ring system in which up to 3 ring atoms are heteroatoms
independently selected from the group consisting of oxygen, sulphur
and nitrogen, which ring are optionally substituted by one or more
substituents independently selected from the group consisting of
C.sub.1-4alkyl optionally substituted by 1, 2 or 3 hydroxy groups,
C.sub.1-4alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl,
C.sub.1-4alkoxyC.sub.1-4alkly, C.sub.1-4alkylthio,
C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, -N(R.sup.6)R.sup.7, -(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy,
C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl, carbonyl,
C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbonyl, carboxy, and
SO.sub.2 N(R.sup.6)R.sup.7, in which R.sup.6, R.sup.7, R.sup.8,
R.sup.9 and p are as defined in claim 1.
43. The method of claim 42, wherein R.sup.10 and R.sup.11 are
methyl.
44. The method of claim 42, wherein R.sup.12 is H, C.sub.1-3alkyl
or a 5- to 6- membered aromatic ring system in which up to 3 ring
atoms are optionally heteroatoms independently selected from the
group consisting of oxygen, sulphur and nitrogen, the ring system
being optionally substituted by hydroxyl.
45. The method of claim 35, wherein the compound of formula (1) is
selected from the group consisting of:
(S)-2-[[6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-met-
hyl-1-(2-
methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4--
methyl-4-isoxazolidinol,
(S)-2-[[6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-met-
hyl- 1-(2-
methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4--
methyl-4-isoxazolidinol,
1-Cyclopropyl-6-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-5-[[(4S)-4-hydroxy-
-4-methyl-
2-isoxazolidinyl]carbonyl]-3-methyl-thieno[2,3-d]pyrimidine-2,4-
(1H,3H)-dione,
(S)-2-[[6-](1H-1,2,3-Benzotriazol-1-yl)methyl]-1,2,3,4-tetrahydro-3-methy-
l-1-(1-
methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-met-
hyl-4-isoxazolidinol,
(S)-2-[[6-](4,5-Dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,4-tetrah-
ydro-1-ethyl-
3-methyl-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxa-
zolidinol,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-
-1-(2-methylpropyl)-6-
(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)--
dione,
(4S)-4-methyl-2-[[1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-6--
(4-
quinolinylmethyl)thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-isoxazolidino-
l,
(4S)-2-[[6-[(2,4-Dichloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-3-meth-
yl-1-(2-
methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-m-
ethyl-4-isoxazolidinol,
(4S)-2-[[6-[(3-Bromo-2-thienyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-m-
ethylpropyl)-
2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxazolidinol-
,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-met-
hylethyl)-6-
[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,3-d]pyrim-
idine-2,4(1H,3H)- dione,
6-[[3,5-Dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-5-[[(4S)-4-hydro-
xy-4-methyl-
2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimid-
ine-2,4-(1H,3H)- dione,
5-[[(4S)-4-Hydroxy-4-methyl-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methyl-
ethyl)-6-
(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thieno[2,3-d]pyrimidine-2,-
4(1H,3H)-dione,
(4S)-2-[[6-[[3,5-Dimethyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methyl]-
1,2,3,4-tetrahydro-3-
methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]--
4-methyl-4- isoxazolidinol,
(4S)-2-[[6-[[3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3-
,4-tetrahydro-
3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl-
]-4-methyl-4- isoxazolidinol,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[(1-phenyl-1H-pyrazol-4-yl)methyl]-thieno[2,3-d]pyrimidine-2,4-(1H,3H)-di-
one,
6-[(8-Fluoroquinolin-4-yl)methyl]-5-{[(4S)-4-hydroxy-4-methylisoxazol-
idin-2-
yl]carbonyl}-1-1-isopropyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,-
3H)-dione,
5-{[(4S)-4-Hydroxy-4-methylisoxazolidin-2-yl]carbonyl}-1-1-isop-
ropyl-3-methyl-6-(4-
pyrimidin-2-ylbenzyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
(5-(2-pyridinyl)-2-thienyl)methyl]-thieno[2,3-d]pyrimidine-2,4-(1H,3H)-di-
one,
6-[(1,3-Dimethyl-1H-5-pyrazolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-
-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-thieno[2,3-d]pyrimid-
ine-2,4-(1H,3H)- dione,
6-[(3,5-Dimethyl-4-isothiozolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidin-
e-2,4-(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6- [[1-(2-thiazolyl)-
1H-pyrazol-4-yl]methyl]thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
6-[(4-Fluorophenyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]c-
arbonyl]-3-
methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
(1H-1,2,3-triazol-1-ylmethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
6-[(6-Chloroimidazo[1,2-a]pyridin-3-yl)methyl]-5-[[(4S)-4-hydroxy-4-methy-
l-2-
isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrim-
idine-2,4-(1H,3H)-dione,
5-[[(4S)-4-hydroxy-4-methylisoxazolidin-2-yl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[[4-(2-pyridinyl)phenyl]methyl]-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione,
(4S)-4-Methyl-2-[[1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-6-[[5-met-
hyl-1-(2-
pyrimidinyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,4-dio-
xothieno[2,3-d]pyrimidin-5 - yl]carbonyl]- 4-isoxazolidinol,
(4S)-2-[[6-[[3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3-
,4-tetrahydro-
3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-
-4-ethyl-4- isoxazolidinol,
(4S)-2-[[6-[[1-(2,3-Dihydro-2-oxo-4-pyrimidinyl)-3,5-dimethyl-1H-pyrazol--
4-
yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothien-
o[2,3-d]pyrimidin-5- yl]carbonyl]-4-methyl-4-isoxazolidinol,
5-[[(4R)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-meth-
ylethyl)-6-
[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,3-d]pyrim-
idine-2,4(1H,3H)- dione, and pharmaceutically acceptable salts
thereof.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 10/542,197, filed on Jul. 14, 2005, which is the national phase
application of International Application No. PCT/SE2004/000052,
filed Jan. 15, 2004, which claims the benefit of Swedish Patent
Application Serial No. 0300119-5, filed Jan. 17, 2003. The contents
of all parent applications are hereby incorporated by reference in
their entireties.
BACKGROUND
[0002] The present invention relates to thienopyrimidinediones,
processes for their preparation, pharmaceutical compositions
containing them and their use in therapy. The invention also
relates to their use in the modulation of autoimmune disease.
[0003] T-cells play an important role in the immune response.
However, in an auto-immune disease T-cells are inappropriately
activated against particular tissues and proliferate, e.g., causing
the inflammation associated with rheumatoid arthritis. Inhibition
of the proliferation of T-cells is beneficial in the modulation of
autoimmune disease. The present invention relates to compounds
which are beneficial in the modulation of autoimmune disease.
DETAILED DESCRIPTION
[0004] In accordance with the present invention, there is provided
a compound of formula (1):
##STR00002##
in which R.sup.1 and R.sup.2 each independently represent a
C.sub.1-6alkyl, C.sub.3-6alkenyl, C.sub.3-5cycloalkylC.sub.1-3alkyl
or C.sub.3-6cycloalkyl; each of which may be optionally substituted
by 1 to 3 halogen atoms; R.sup.3is a group CO-G or SO.sub.2-G in
which G is a 5- or 6-membered ring containing a nitrogen atom and a
second heteroatom selected from the group consisting of oxygen and
sulphur adjacent to the nitrogen; the ring being substituted by at
least one group selected from the group consisting of halogen or
C.sub.1-4 alkyl optionally substituted by up to five halogen atoms,
and optionally substituted by up to a further 4 groups
independently selected from the group consisting of halogen,
hydroxyl and C.sub.1-4 alkyl optionally substituted by up to five
halogen atoms; Q is CR.sup.4R.sup.5 in which R.sup.4 is hydrogen,
fluorine or C.sub.1-6 alkyl and R.sup.5 is hydrogen, fluorine or
hydroxy; Ar is a 5- to 10-membered aromatic ring system in which up
to 4 ring atoms are heteroatoms independently selected from the
group consisting of nitrogen, oxygen and sulphur, the ring system
being optionally substituted by one or more substituents
independently selected from the group consisting of C.sub.1-4alkyl
(optionally substituted by 1, 2 or 3 hydroxy groups),
C.sub.1-4alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl,
C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, --N(R.sup.6)R.sup.7 and --(CH.sub.2)pN(R.sup.8)R.sup.9,
hydroxy, C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl,
carbamoyl, C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbamoyl,
carboxy, and SO.sub.2N(R.sup.6)R.sup.7; or Ar is optionally
substituted by a 5 or 6 membered aromatic ring containing up to 4
heteroatoms independently selected from nitrogen, oxygen and
sulphur, and which is optionally substituted by one or more
substituents independently selected from the group consisting of
C.sub.1-4alkyl (optionally substituted by 1, 2 or 3 hydroxy
groups), C.sub.1-4alkoxy, halogen, haloalkyl, dihaloalkyl,
trihaloalkyl, C.sub.1-4alkoxyC.sub.1-4alkyl, C.sub.1-4alkylthio,
C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl, oxo, thioxo, nitro,
cyano, --N(R.sup.6)R.sup.7, --(CH.sub.2)pN(R.sup.8)R.sup.9,
hydroxy, C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphinyl,
carbamoyl, C.sub.1-4alkylcarbamoyl, di-(C.sub.1-4alkyl)carbamoyl,
carboxy, and SO.sub.2N(R.sup.6)R.sup.7; p is 1, 2, 3 or 4; R.sup.6
and R.sup.7 each independently represent a hydrogen atom,
C.sub.1-4alkanoyl or C.sub.1-4alkyl, or together with the nitrogen
atom to which they are attached form a 5- to 7-membered saturated
heterocyclic ring; and R.sup.8 and R.sup.9 each independently
represent a hydrogen atom, C.sub.1-4alkanoyl or C.sub.1-4alkyl, or
together with the nitrogen atom to which they are attached form a
5- to 7-membered saturated heterocyclic ring; and pharmaceutically
acceptable salts and solvates thereof.
[0005] Alkyl groups, whether alone or as part of another group, can
be straight chained or branched. They will generally comprise from
1 to 6 and suitably from 1 to 4 carbon atoms.
[0006] Examples of haloalkyl groups are haloC.sub.1-4alkyl groups
such as chloro- or fluoromethyl.
[0007] Examples of dihaloalkyl groups are dihaloC.sub.1-4alkyl
groups such as difluoro- or dichloromethyl. Examples of
trihaloalkyl groups are trihaloC.sub.1-4alkyl groups such as
trifluoromethyl.
[0008] It will be understood that a compound of the formula (1) or
a salt thereof may exhibit the phenomenon of tautomerism and that
the drawings within this specification represent only one of the
possible tautomeric forms. It is to be understood that the
invention encompasses any tautomeric form.
[0009] Certain compounds of formula (1) are capable of existing in
stereoisomeric forms. It will be understood that the invention
encompasses all geometric and optical isomers of the compounds of
formula (1) and mixtures thereof including racemates. These also
form an aspect of the present invention.
[0010] Preferably R.sup.1 is C.sub.1-6 alkyl or C.sub.3-6
cycloalkyl. More preferably R.sup.1 is ethyl, propyl, butyl or
cyclopropyl. Most preferably R.sup.1 is ethyl, isobutyl, isopropyl
or cyclopropyl.
[0011] Preferably R.sup.2 is C.sub.1-6alkyl such as ethyl or
methyl, more preferably methyl.
[0012] Suitably G in group R.sup.3 is a 5-membered ring containing
an oxygen atom, such as an isoxazolidinyl ring. Preferably the ring
G is substituted by a C.sub.1-4 alkyl group such as methyl. In a
particular embodiment, the ring G is substituted by a
C.sub.1-4alkyl group such as methyl and by at least one additional
substitutent selected from halogen, hydroxyl and C.sub.1-4 alkyl
(which may be optionally substituted by up to five halogen atoms).
In particular, the ring G is substituted by a C.sub.1-4alkyl group
and a hydroxy group, and preferably ring G is substituted by methyl
and a hydroxy substituent. A hydroxyl substituent may not be
attached to a ring carbon atom that is bonded to a ring
heteroatom.
[0013] The group G is preferably linked to the CO or SO.sub.2 group
through its ring nitrogen atom. Particular examples of the group G
are is 4-hydroxy-4-methyl-isoxazolidin-2-yl.
[0014] Preferably R.sup.3is a group CO-G as defined above in which
the ring G is linked via a nitrogen atom. More preferably R.sup.3
is a group CO-G where G is a 5-membered ring as described
above.
[0015] Most preferably R.sup.3 is
4-hydroxy-4-methyl-isoxazolidin-2-yl carbonyl.
[0016] Suitably Q is CR.sup.5R.sup.6 where R.sup.5 is hydrogen,
C.sub.1-6 alkyl and R.sup.6 is hydrogen. Preferably Q is
CH.sub.2.
[0017] Examples of 5-10 membered mono- or bi-cyclic aromatic ring
systems for Ar include thienyl, furanyl, pyrrolyl, pyrrolopyridino,
imidazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl,
oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, oxadiazolyl,
thiadiazolyl, triazolyl, tetrazolyl and quinolyl. Particular
examples are thienyl, pyrazolyl, thiazolyl or triazolyl ring, any
of which may be optionally substituted.
[0018] A further example of Ar is phenyl, which may be optionally
substituted as described above.
[0019] Where Ar is a bicyclic aromatic ring system, particular
examples are a benzotriazole, pyrrolo[2,3-b]pyridine, quinoline
ring or imidazopyridinyl ring, and in particular a benzotriazole,
pyrrolo[2,3-b]pyridine or a quinoline ring
[0020] Suitably Ar is a 5-membered aromatic ring containing two
heteroatoms optionally substituted as defined above or Ar is a 9-
or 10-membered bicyclic ring containing one, two or three
heteroatoms and optionally substituted as defined above. Preferably
Ar is a 5-membered aromatic ring containing two heteroatoms
optionally substituted as defined above.
[0021] Particular substituents for the group Ar are one or more
substituents independently selected from C.sub.1-4alkyl, halogen,
haloalkyl, dihaloalkyl, trihaloalkyl, or a 5 or 6 membered aromatic
ring containing up to 4 heteroatoms independently selected from
nitrogen, oxygen and sulphur, which may itself be optionally
substituted as described above, but in particular may be
substituted by oxo.
[0022] For instance, Ar may be optionally substituted by one or
more substituents selected from methyl, chloro, bromo, fluoro,
trifluoromethyl, pyrimidinyl (such as 2-pyrimidinyl), pyridyl (such
as 2-pyridyl or 4-pyridyl) or phenyl.
[0023] In a particular embodiment, Ar is a thienyl, pyrazole or
thiazole ring each substituted by two or three alkyl, halogen,
trifluoromethyl substituents and/or also substituted by a
2-pyrimidinyl or 2-pyridyl group.
[0024] A particular example of Ar is an optionally substituted
pyrazole ring. Preferably Ar is a substituted pyrazole ring.
[0025] For instance, Ar is suitably a group of sub-formula (i)
##STR00003##
where R.sup.10 and R.sup.11 are independently selected from H,
C.sub.1-6alkyl, or haloC.sub.1-6alkyl; and R.sup.12 is selected
from H, C.sub.1-6alkyl, or haloC.sub.1-6alkyl or a 5- to 6-membered
aromatic ring system wherein up to 3 ring atoms may be heteroatoms
independently selected from oxygen, sulphur and nitrogen, which
ring may be optionally substituted by one or more substituents
independently selected from C.sub.1-4alkyl (optionally substituted
by 1,2 or 3 hydroxy groups), C.sub.1-4alkoxy, halogen, haloalkyl,
dihaloalkyl, trihaloalkyl, C.sub.1-4alkoxyC.sub.1-4alkyl,
C.sub.1-4alkylthio, C.sub.1-4alkoxycarbonyl, C.sub.2-4alkanoyl,
oxo, thioxo, nitro, cyano, --N(R.sup.6)R.sup.7,
--(CH.sub.2)pN(R.sup.8)R.sup.9, hydroxy, C.sub.1-4alkylsulphonyl,
C.sub.1-4alkylsulphinyl, carbamoyl, C.sub.1-4alkylcarbamoyl,
di-(C.sub.1-4alkyl)carbamoyl, carboxy, or
SO.sub.2N(R.sup.6)R.sup.7, in which R.sup.6, R.sup.7, R.sup.8,
R.sup.9 and p are as defined above.
[0026] In R.sup.10 and R.sup.11 are selected from H or
C.sub.1-3alkyl, such as methyl.
[0027] In particular, both R.sup.10 and R.sup.11 is C.sub.1-3alkyl
such as methyl.
[0028] Suitably R.sup.12 is selected from H, C.sub.1-3alkyl (such
as methyl) or a 5- to 6-membered aromatic ring system wherein up to
3 ring atoms may be heteroatoms independently selected from oxygen,
sulphur and nitrogen, optionally substituted by oxo. Where R.sup.12
is a 5- to 6-membered aromatic ring system, particular examples of
such systems are phenyl, pyridyl (such as 2-pyridyl or 4-pyridyl),
pyrimidinyl (such as 2-pyrimidinyl) or thiazolyl (such as
2-thiazolyl).
[0029] Preferably R.sup.12 is H, pyridyl or pyrimidinyl, and most
preferably pyridyl or pyrimidinyl.
[0030] In an embodiment of the invention, Ar is a pyrazole ring,
substituted by alkyl such as C.sub.1-6alkyl, or haloC.sub.1-6alkyl
such as or trifluoromethyl substituents and/or also substituted by
a 2-pyrimidinyl or 2-pyridyl group.
[0031] Where R.sup.6 and R.sup.7 and R.sup.8 and R.sup.9 form a 5
to 7 membered saturated heterocyclic ring, examples of suitable
rings include morpholine, piperidine, piperazine and
pyrrolidine.
[0032] Preferred compounds of formula (1) include:
[0033]
(S)-2-[[6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-
-3-methyl-1-(2-methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbony-
l]-4-methyl-4-isoxazolidinol,
[0034]
(S)-2-[[6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-
-3-methyl-1-(2-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl-
]-4-methyl-4-isoxazolidinol,
[0035]
1-Cyclopropyl-6-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-5-[[(4S)-4-h-
ydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-thieno[2,3-d]pyrimidin-
e-2,4(1H,3H)-dione,
[0036]
(S)-2-[[6-[(1H-1,2,3-Benzotriazol-1-yl)methyl]-1,2,3,4-tetrahydro-3-
-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]--
4-methyl-4-isoxazolidinol,
[0037]
(S)-2-[[6-[(4,5-Dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,4--
tetrahydro-1-ethyl-3-methyl-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl-
]-4-methyl-4-isoxazolidinol,
[0038]
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(-
2-methylpropyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimi-
dine-2,4-(1H,3H)-dione,
[0039]
(4S)-4-methyl-2-[[1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-6--
(4-quinolinylmethyl)thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-isoxazolidinol-
,
[0040]
(4S)-2-[[6-[(2,4-Dichloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-3--
methyl-1-(2-methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]--
4-methyl-4-isoxazolidinol,
[0041]
(4S)-2-[[6-[(3-Bromo-2-thienyl)methyl]-1,2,3,4-tetrahydro-3-methyl--
1-(2-methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methy-
l-4-isoxazolidinol,
[0042]
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(-
1-methylethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-th-
ieno[2,3-d]pyrimidine-2,4(1H,3H)-dione,
[0043]
6-[[3,5-Dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-5-[[(4S)-4-
-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thi-
eno[2,3-d]pyrimidine-2,4-(1H,3H)-dione,
[0044]
5-[[(4S)-4-Hydroxy-4-methyl-isoxazolidinyl]carbonyl]-3-methyl-1-(1--
methylethyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thieno[2,3-d]pyrimidi-
ne-2,4(1H,3H)-dione,
[0045]
(4S)-2-[[6-[[3,5-Dimethyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methyl]-1-
,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimi-
din-5-yl]carbonyl]-4-methyl-4-isoxazolidinol,
[0046]
(4S)-2-[[6-[[3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-
-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyri-
midin-5-yl]carbonyl]-4-methyl-4-isoxazolidinol,
[0047]
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(-
1-methylethyl)-6-[(1-phenyl-1H-pyrazol-4-yl)methyl]-thieno[2,3-d]pyrimidin-
e-2,4-(1H,3H)-dione
[0048]
6-[(8-Fluoroquinolin-4-yl)methyl]-5-{[(4S)-4-hydroxy-4-methylisoxaz-
olidin-2-yl]carbonyl}-1-isopropyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3-
H)-dione,
[0049]
5-{[(4S)-4-Hydroxy-4-methylisoxazolidin-2-yl]carbonyl}-1-isopropyl--
3-methyl-6-(4-pyrimidin-2-ylbenzyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dion-
e,
[0050]
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(-
1-methylethyl)-6-[(5-(2-pyridinyl)-2-thienyl)methyl]-thieno[2,3-d]pyrimidi-
ne-2,4-(1H,3H)-dione,
[0051]
6-[(1,3-Dimethyl-1H-5-pyrazolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-
-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-thieno[2,3-d]pyrimi-
dine-2,4-(1H,3H)-dione,
[0052]
6-[(3,5-Dimethyl-4-isothiozolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-
-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimid-
ine-2,4-(1H,3H)-dione,
[0053]
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(-
1-methylethyl)-6-[[1-(2-thiazolyl)-1H-pyrazol-4-yl]methyl]-thieno[2,3-d]py-
rimidine-2,4-(1H,3H)-dione,
[0054]
6-[(4-Fluorophenyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolid-
inyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3-
H)-dione,
[0055]
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(-
1-methylethyl)-6-(1H-1,2,3-triazol-1-ylmethyl)thieno[2,3-d]pyrimidine-2,4--
(1H,3H)-dione,
[0056]
6-[(6-Chloroimidazo[1,2-a]pyridin-3-yl)methyl]-5-[[(4S)-4-hydroxy-4-
-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]-
pyrimidine-2,4-(1H,3H)-dione,
[0057]
5-[[(4S)-4-hydroxy-4-methylisoxazolidin-2-yl]carbonyl]-3-methyl-1-(-
1-methylethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-thieno[2,3-d]pyrimidine-2-
,4(1H,3H)-dione,
[0058]
(4S)-4-Methyl-2-[[1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-6-[-
[5-methyl-(2-pyrimidinyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,4--
dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-isoxazolidinol,
[0059]
(4S)-2-[[6-[[3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-
-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrim-
idin-5-yl]carbonyl]-4-ethyl-4-isoxazolidinol,
[0060]
(4s)-2-[[6-[[1-(2,3-Dihydro-2-oxo-4-pyrimidinyl)-3,5-dimethyl-1h-py-
razol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-
thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxazolidinol,
[0061]
5-[[(4R)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(-
1-methylethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-th-
ieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
and pharmaceutically acceptable salts thereof.
[0062] Salts for use in pharmaceutical compositions will be
pharmaceutically acceptable salts, but other salts may be useful in
the production of the compounds of formula I and their
pharmaceutically acceptable salts. Pharmaceutically acceptable
salts of the invention may, for example, include acid addition
salts of the compounds of formula I as hereinbefore defined which
are sufficiently basic to form such salts. Such acid addition salts
include for example salts with inorganic or organic acids affording
pharmaceutically acceptable anions such as with hydrogen halides
(especially hydrochloric or hydrobromic acid of which hydrochloric
acid is particularly preferred) or with sulphuric or phosphoric
acid, or with trifluoroacetic, citric or maleic acid. Suitable
salts include hydrochlorides, hydrobromides, phosphates, sulphates,
hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates,
benzoates, citrates, maleates, fumarates, succinates, lactates and
tartrates. In addition where the compounds of formula I are
sufficiently acidic, pharmaceutically acceptable salts may be
formed with an inorganic or organic base which affords a
pharmaceutically acceptable cation. Such salts with inorganic or
organic bases include for example an alkali metal salt, such as a
sodium or potassium salt, an alkaline earth metal salt such as a
calcium or magnesium salt, an ammonium salt or for example a salt
with methylamine, dimethylamine, trimethylamine, piperidine,
morpholine or tris-(2-hydroxyethyl)amine.
[0063] Preferred salts include an acid addition salt such as a
hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate,
tartrate, citrate, oxalate, methanesulfonate or p-toluenesulfonate,
or an alkali metal salt such as a sodium or potassium salt.
[0064] Compounds of the invention can be prepared by routes
analogous to those known in the art. Particular examples are given
below.
[0065] In a further aspect the invention provides a process for the
preparation of a compound of formula (1) which comprises:
[0066] a) when R.sup.3 is a group COG, reacting a compound of the
formula (10):
##STR00004##
with G-H;
[0067] b) when Q is methylene, reacting a compound of the formula
(11):
##STR00005##
with a compound of the formula Ar-H;
[0068] c) when Q is methylene, reducing a compound of the formula
(12):
##STR00006##
[0069] d) reacting a compound of the formula (11) or (13) to form
Ar by primary ring synthesis:
##STR00007##
[0070] e) reacting a compound of the formula (14) with
R.sup.1-L.sup.2;
##STR00008##
[0071] f) when R.sup.3 is SO.sub.2G reacting a compound of formula
(15)
##STR00009##
with a compound G-H; in which L.sup.a, L, L.sup.1 and L.sup.2 are
leaving groups and R.sup.1, R.sup.2, R.sup.3, G, Q and Ar are as
defined above or are protected derivatives thereof, and optionally
after a), b), c), d), e) or f) converting the compound of the
formula (1) into a further compound of formula (1) and/or forming a
pharmaceutically acceptable salt or solvate thereof.
[0072] In particular in the compound of formula (15), Q is
methylene.
[0073] Suitable leaving groups for L.sup.a, L, L.sup.1 and L.sup.2
would be apparent to a skilled chemist, depending upon the nature
of the reaction being conducted. Examples of leaving groups may
include halo, such as chloro, bromo or iodo, anhydride groups such
as acetic anhydride, esters such as mesylate or tosylate, and
hydroxy.
[0074] The reaction between a compound of the formula (10) and
compound G-H, where G is has a nitrogen attached to the hydrogen
atom shown, is conveniently carried out under amide bond forming
reaction conditions, in which case, L.sup.a is hydroxy. For
example, in the presence of a coupling agent such as
dicyclohexylcarbodiimide or
1-ethyl-3-(3-dimethylaminopropyl)ethylcarbodiimide. Optionally a
base may be used, preferably an organic base such as triethylamine.
Suitable solvents are usually aprotic solvents, for example
dimethylformamide or chlorinated solvents, for example
dichloromethane or trichloromethane. Additionally, a compound which
catalyses this type of amide bond formation reaction, such as
1-hydroxybenzotriazole, may be present. The temperature is usually
in the range of about -30.degree. C. to about 60.degree. C.,
preferably at or near ambient temperature.
[0075] The reaction between a compound of the formula (11) and Ar
is normally carried out in the presence of a strong base such as
sodium hydride. Suitable leaving groups include halo, in particular
bromo. The reaction is conveniently carried out in an inert solvent
such as tetrahydrofuran, preferably at or around ambient
temperature. In some circumstances, for example when Ar contains
ring nitrogen atoms which do not need to be deprotonated, a milder
base, such as sodium bicarbonate can be used. This reaction is
conveniently used to prepare compounds in which Ar is linked
through a ring nitrogen atom. However, it is possible to use this
process to prepare a compound in which Ar is linked via a ring
carbon atom. This can be achieved by using a strong base and a zinc
salt such as zinc chloride and optionally sodium iodide as a
catalyst.
[0076] A compound of formula (12) can be reduced to the
corresponding methylene compound using standard reduction
conditions for hydroxy groups known in the art. For example, it can
be protonated with an acid such as trifluoroacetic acid and reduced
with a trialkylsilane. Alternatively the hydroxy group could be
converted to a stronger leaving group, such as mesylate or tosylate
and the resulting compound hydrogenated in a non-hydroxylic
solvent, preferably tetrahydrofuran, with a catalyst such as
palladium on charcoal, in a temperature range of 0.degree. C. to
50.degree. C., preferably at ambient temperature and a pressure of
1 to 5 bar.
[0077] The group -Q-Ar is conveniently formed on a compound of
formula (11) or (13) by primary ring synthesis. Here, reference is
made to the compendiums "The Chemistry of Heterocyclic Compounds"
E. C. Taylor and A. Weissberger (published by John Wiley and Sons)
and "Comprehensive Heterocyclic Chemistry", A. R Katritzky and C. W
Rees (published by Pergamon Press (Elsevier)). For examples of the
preparation of a compound of the formula (1) in which Ar is
3,5-dimethylpyrazol-4-yl or 1,3,5-trimethylpyrazol-4-yl, see
examples 11 and 12 in the specific examples.
[0078] A compound of the formula (14) may be reacted with a
compound of formula R.sup.1-L.sup.2 in the presence of a mild base,
such as potassium carbonate, in a dipolar aprotic solvent such as
DMF, in a temperature range of ambient temperature to 170.degree.
C.
[0079] A particular example of L.sup.1 in formula (15) is
chlorine.
[0080] A compound of the formula (1) may be prepared from another
compound of formula (1) by chemical modification. For example a
compound of the formula (1) wherein Q is methylene can be oxidised
to a compound of the formula (1) wherein Q is carbonyl. A preferred
oxidising agent is 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ)
in an inert organic solvent such as tetrahydrofuran. In some
circumstances oxidation can be effected by exposure of the
methylene compound to air.
[0081] Alternatively or additionally, compounds of formula (1)
where Ar is a group of sub-formula (i) above, wherein R.sup.12 is
hydrogen can be converted to compounds of formula (i) where
R.sup.12 is other than hydrogen by reaction with a compound of
formula (XV)
R.sup.12'-L'' (XV)
where R.sup.12' is a group R.sup.12 other than hydrogen, and L'' is
a leaving group such as halo, and in particular bromo. Such a
reaction may be carried out in an organic solvent such as
acetonitrile or dioxan. If necessary the reaction can be carried
out in the presence of a base such as an alkali metal carbonate,
for instance potassium carbonate, and in the presence of a catalyst
such as a copper salt like copper iodide. Also if necessary, the
reaction can be effected under an inert atmosphere such as
nitrogen.
[0082] Intermediates of the formulae (10) may be formed from a
compound of the formula (16):
##STR00010##
in which R.sup.20 is C.sub.1-6alkyl, for example methyl or ethyl,
and R.sup.21 is either --CH.sub.2L (in which L is as hereinabove
defined) or --CH(OH)Ar.
[0083] A compound of formula (16) in which R.sup.21 is --CH.sub.2L
may be reacted with Ar under similar conditions to those described
for process b) above.
[0084] When Ar is linked via a ring carbon atom, a compound of
formula (15) in which R.sup.21 is --CH(OH)Ar may be reduced using
similar conditions to those described for process c) above.
[0085] A compound of the formula (12) or (16) wherein R.sup.21 is
--CH(OH)Ar may be formed by reacting a compound of the formula
(17):
##STR00011##
(in which R.sup.22 is R.sup.3 or --CO.sub.2R.sup.20, as
appropriate) with a compound of formula Ar--CHO in the presence of
a strong base such as a lithium dialkylamide, for example, lithium
diisopropylamide, in an inert organic solvent such as
tetrahydrofuran and initially at a low temperature, such as
-78.degree. C. and subsequently allowing it to warm to ambient
temperature.
[0086] The intermediates are in general prepared from a compound of
the formula (18):
##STR00012##
in which R.sup.23 is hydrogen or methyl.
[0087] When R.sup.21 is --CH(OH)Ar, R.sup.23 is hydrogen and the
compound of formula (17) may be reacted with Ar--CHO as described
above for the compound of formula (16).
[0088] When R.sup.21 is --CH.sub.2L, R.sup.23 is methyl which is
converted to --CH.sub.2L by for example halogenation. When L is
bromo, the methyl group may be brominated using a standard
brominating agent such as N-bromosuccinimide under standard
conditions.
[0089] A compound of formula (18) wherein R.sup.23 is hydrogen may
be formed by firstly reacting a compound of formula (19):
##STR00013##
with an alkylbromopyruvate, such as ethylbromopyruvate, in the
presence of a mild base such as an alkali carbonate, for example
potassium carbonate in a polar solvent e.g. DMF at a temperature
between 5.degree. C. and 50.degree. C. and then secondly treating
the resulting adduct with a Lewis acid preferably titanium
tetrachloride, in an inert solvent, e.g., dichloromethane at a
temperature between -20.degree. C. and 50.degree. C., preferably
between 0.degree. C. and 25.degree. C.
[0090] A compound of formula (18) in which R.sup.23 is methyl may
be formed by firstly reacting a compound of formula (19) with an
alkyl 3-bromo-2-oxobutanoate such as methyl 3-bromo-2-oxobutanoate
in the presence of a mild base such as an alkali carboxylate, for
example sodium acetate in a polar solvent such as DMF, or
preferably water, at a temperature between 5.degree. C. and
50.degree. C. and then secondly treating the resulting adduct with
a Lewis acid, preferably titanium tetrachloride, in an inert
solvent, e.g., dichloromethane at a temperature between -20.degree.
C. and 50.degree. C., preferably between 0.degree. C. and
25.degree. C.
[0091] A compound of formula (18) may be formed by reacting a
compound of formula (20):
##STR00014##
(in which R.sup.24 is C.sub.1-4alkyl, for example ethyl) with
acetyl cyanate in an inert solvent, for example toluene, at a
temperature of from 0.degree. C. to 50.degree. C., and then
treating the product of that conversion with a solution of a metal
alkoxide in the alkanol (e.g., sodium methoxide in methanol) at a
temperature of from 0.degree. C. to 30.degree. C., in the presence
of a compound of formula R.sup.2-L.sup.1 (in which L.sup.1 is a
leaving group, e.g., iodide).
[0092] A compound of formula (20) may be prepared by the reaction
of a compound of formula (20): R.sup.1--N.dbd.C.dbd.S with a Wittig
compound, for example a compound of the formula (22):
##STR00015##
(in which R' is phenyl or substituted phenyl such as tolyl) in an
inert solvent, for example THF, at a temperature of from 20.degree.
C. to 80.degree. C., and treatment of the resulting adduct in situ
with a compound of formula (23):
##STR00016##
at a temperature of from -78.degree. C. to 60.degree. C.
[0093] A compound of formula (19) may be formed by reacting a
compound of formula (24):
##STR00017##
with an alkaline metal thiol, such as sodium thiol, in a polar
solvent, such as an alcohol, for example ethanol, in a temperature
range of 10.degree. C. to 50.degree. C.
[0094] A compound of formula (23) may be formed by reacting a
compound of formula (25):
##STR00018##
with a compound of formula R.sup.1-L.sup.2 under conditions
described for process e) above.
[0095] A compound of formula (15) can be prepared by reacting a
compound of formula (26):
##STR00019##
in which L''' is a leaving group, and in particular a halo group
such as bromo, with a Grignard reagent followed by addition of
SO.sub.2, oxidation and chlorination. The reaction is carried out
in a suitable solvent such as THF at a temperature of -70.degree.
C. to 30.degree. C., preferably at -20.degree. C. to 20.degree. C.
The resulting sulphinic acid can be oxidised to the corresponding
sulphonic acid and chlorinated, for example using PCl.sub.5.
[0096] Compounds of formula (26) are prepared by treating the
corresponding halo derivative, such as the bromo derivative, with a
strong base such as lithium diisopropylamide at reduced temperature
followed by treatment with a compound ArCHO. The reaction is
suitable carried out in THF at a temperature of -70.degree. C. to
30.degree. C., preferably at -50.degree. C. to 0.degree. C.
[0097] The precursor halo compounds are prepared by halogenation,
and in particular bromination, of a compound of formula (27):
##STR00020##
[0098] The reaction can be carried out using for instance, bromine
in chloroform at a temperature of from -10.degree. C. to 60.degree.
C., preferably at about ambient temperature.
[0099] Starting materials as defined above are available
commercially or can be prepared using routine chemistry known in
the art.
[0100] The compounds of formula (1) above may be converted to a
pharmaceutically acceptable salt or solvate thereof.
[0101] Certain compounds of formula (1) are capable of existing in
stereoisomeric forms. It will be understood that the invention
encompasses all geometric and optical isomers of the compounds of
formula (1) and mixtures thereof including racemates. These also
form an aspect of the present invention.
[0102] Isomers may be resolved or separated by conventional
techniques, e.g., chromatography or fractional crystallisation.
Enantiomers may be isolated by separation of a racemic or other
mixture of the compounds using conventional techniques (e.g.,
chiral High Performance Liquid Chromatography (HPLC)).
Alternatively the desired optical isomers may be made by reaction
of the appropriate optically active starting materials under
conditions which will not cause racemisation, or by derivatisation,
for example with a homochiral acid followed by separation of the
diastereomeric derivatives by conventional means (e.g., HPLC,
chromatography over silica) or may be made with achiral starting
materials and chiral reagents. All stereoisomers are included
within the scope of the invention.
[0103] The compounds of the invention may be isolated from their
reaction mixtures using conventional techniques.
[0104] The compounds of the invention are useful because they
possess pharmacological activity in human and non-human animals.
They are indicated as pharmaceuticals for use in the (prophylactic)
treatment of autoimmune, inflammatory, proliferative and
hyperproliferative diseases and immunologically mediated diseases
including rejection of transplanted organs or tissues and Acquired
Immunodeficiency Syndrome (AIDS).
[0105] Examples of these conditions are:
[0106] (1) (the respiratory tract) airways diseases including
chronic obstructive pulmonary disease (COPD); asthma, such as
bronchial, allergic, intrinsic, extrinsic and dust asthma,
particularly chronic or inveterate asthma (e.g., late asthma and
airways hyper-responsiveness); bronchitis; acute, allergic,
atrophic rhinitis and chronic rhinitis including rhinitis caseosa,
hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and
rhinitis medicamentosa; membranous rhinitis including croupous,
fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis;
seasonal rhinitis including rhinitis nervosa (hay fever) and
vasomotor rhinitis; sarcoidosis, farmer's lung and related
diseases, fibroid lung and idiopathic interstitial pneumonia;
[0107] (2) (bone and joints) rheumatoid arthritis, seronegative
spondyloarthropathies (including ankylosing spondylitis, psoriatic
arthritis and Reiter's disease), Behcet's disease, Sjogren's
syndrome and systemic sclerosis;
[0108] (3) (skin) psoriasis, atopical dermatitis, contact
dermatitis and other eczmatous dermitides, seborrhoetic dermatitis,
Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa,
urticaria, angiodermas, vasculitides, erythemas, cutaneous
eosinophilias, uveitis, Alopecia areata and vernal
conjunctivitis;
[0109] (4) (gastrointestinal tract) Coeliac disease, proctitis,
eosinopilic gastro-enteritis, mastocytosis, Crohn's disease,
ulcerative colitis, food-related allergies which have effects
remote from the gut, e.g., migraine, rhinitis and eczema;
[0110] (5) (other tissues and systemic disease) multiple sclerosis,
atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus
erythematosus, systemic lupus, erythematosus, Hashimoto's
thyroiditis, myasthenia gravis, type I diabetes, nephrotic
syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous
leprosy, sezary syndrome and idiopathic thrombocytopenia
pupura;
[0111] (6) (allograft rejection) acute and chronic following, for
example, transplantation of kidney, heart, liver, lung, bone
marrow, skin and cornea; and chronic graft versus host disease;
and
[0112] (7) cancer.
[0113] Accordingly, the present invention provides a compound of
formula (1) or a pharmaceutically acceptable salt thereof as
hereinbefore defined for use in therapy.
[0114] In another aspect, the invention provides the use of a
compound of formula (1) or a pharmaceutically acceptable salt
thereof as hereinbefore defined in the manufacture of a medicament
for use in therapy.
[0115] In the context of the present specification, the term
"therapy" also includes "prophylaxis" unless there are specific
indications to the contrary. The terms "therapeutic" and
"therapeutically" should be construed accordingly.
[0116] Prophylaxis is expected to be particularly relevant to the
treatment of persons who have suffered a previous episode of, or
are otherwise considered to be at increased risk of, the disease or
condition in question. Persons at risk of developing a particular
disease or condition generally include those having a family
history of the disease or condition, or those who have been
identified by genetic testing or screening to be particularly
susceptible to developing the disease or condition.
[0117] The invention further provides a method of effecting
immunosuppression (e.g., in the treatment of allograft rejection)
which comprises administering to a patient a therapeutically
effective amount of a compound of formula (1) or a pharmaceutically
acceptable salt thereof as hereinbefore defined.
[0118] The invention still further provides a method of treating,
or reducing the risk of, an airways disease (e.g., asthma or COPD)
in a patient suffering from, or at risk of, said disease, which
comprises administering to the patient a therapeutically effective
amount of a compound of formula (1) or a pharmaceutically
acceptable salt thereof as hereinbefore defined.
[0119] For the above-mentioned therapeutic uses the dosage
administered will, of course, vary with the compound employed, the
mode of administration, the treatment desired and the disorder
indicated. However, in general, for effecting immunosuppression,
the daily dosage of the compound of formula (1) will be in the
range from 0.1 mg/kg, preferably from 0.3 mg/kg, more preferably
from 0.5 mg/kg and still more preferably from 1 mg/kg up to and
including 30 mg/kg. For the treatment of airways diseases, the
daily dosage of the compound of formula (1) will typically be in
the range from 0.001 mg/kg to 30 mg/kg.
[0120] The compounds of formula (1) and pharmaceutically acceptable
salts thereof may be used on their own but will generally be
administered in the form of a pharmaceutical composition in which
the formula (1) compound/salt/solvate (active ingredient) is in
association with a pharmaceutically acceptable adjuvant, diluent or
carrier. Depending on the mode of administration, the
pharmaceutical composition will preferably comprise from 0.05 to
99% w (per cent by weight), more preferably less than 80% w, e.g.,
from 0.10 to 70% w, and even more preferably less than 50% w, of
active ingredient, all percentages by weight being based on total
composition.
[0121] Thus, the present invention also provides a pharmaceutical
composition comprising a compound of formula (1) or a
pharmaceutically acceptable salt thereof as hereinbefore defined,
in association with a pharmaceutically acceptable adjuvant, diluent
or carrier.
[0122] The invention further provides a process for the preparation
of a pharmaceutical composition of the invention which comprises
mixing a compound of formula (1) or a pharmaceutically acceptable
salt thereof as hereinbefore defined, with a pharmaceutically
acceptable adjuvant, diluent or carrier.
[0123] The pharmaceutical composition of the invention may be
administered topically (e.g., to the lung and/or airways or to the
skin) in the form of solutions, suspensions, heptafluoroalkane
aerosols and dry powder formulations; or systemically, e.g., by
oral administration in the form of tablets, capsules, syrups,
powders or granules, or by parenteral administration in the form of
solutions or suspensions, or by subcutaneous administration or by
rectal administration in the form of suppositories or
transdermally.
[0124] The ability of compounds which can inhibit
PMA/ionomycin-stimulated peripheral blood mononuclear cell
proliferation can be assessed, for example using the procedure set
out below.
[0125] The invention will now be illustrated in the following
Examples in which, unless otherwise stated:
[0126] (i) evaporations were carried out by rotary evaporation in
vacuo and work-up procedures were carried out after removal of
residual solids such as drying agents by filtration;
[0127] (ii) operations were carried out at ambient temperature,
that is in the range 18-25.degree. C. and under an atmosphere of an
inert gas such as argon or nitrogen;
[0128] (iii) yields are given for illustration only and are not
necessarily the maximum attainable;
[0129] (iv) the structures of the end-products of the formula I
were confirmed by nuclear (generally proton) magnetic resonance
(NMR) and mass spectral techniques; proton magnetic resonance
chemical shift values were measured on the delta scale and peak
multiplicities are shown as follows: s, singlet; d, doublet; t,
triplet; m, multiplet; br, broad; q, quartet, quin, quintet;
[0130] (v) intermediates were not generally fully characterised and
purity was assessed by thin layer chromatography (TLC),
high-performance liquid chromatography (HPLC), mass spectrometry
(MS), infra-red (IR) or NMR analysis;
[0131] Abbreviations
[0132] 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone DDQ
[0133] Dimethylformamide DMF
[0134] Tetrahydrofuran THF
[0135] The following examples illustrate the invention.
EXAMPLE 1
(S)-2-[[6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahvdro-3-meth-
yl-1-(2-methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-me-
thyl-4-isoxazolidinol
##STR00021##
[0136] a)
2-[[(2S)-2-Methyloxiranyl]methoxyl]-1H-isoindole-1,3(2H)-dione
[0137] A mixture of N-hydroxypthalimide (5.3 g),
[(2S)-2-methyloxiran-2-yl]methyl 3-nitrobenzenesulfonate (5.9 g)
and triethylamine (10.6 ml) in dichloromethane (15 ml) was stirred
under nitrogen at ambient temperature for 24 hours.
[0138] The reaction mixture was poured onto a silica column and
eluted with dichloromethane to give the sub-title compound as a
white solid (3.1 g).
[0139] MS (APCI) 234 [M+H].sup.+.
[0140] .delta. .sup.1H.sub.CDCl3 1.63 (3H, s), 2.69 (1H, d), 2.76
(1H, d), 4.17 (1H, d), 4.21 (1H, d) 7.73-7.78 (2H, m), 7.82-7.87
(2H, m).
b)
2-[[(2R)-3-Chloro-2-hydroxy-2-methylpropyl]oxy]-1H-isoindole-1,3(2H)-di-
one
[0141] The product of part a) (3.0 g) was treated with concentrated
hydrochloric acid (12 ml) and stirred at ambient temperature for 2
hours.
[0142] The mixture was partitioned between water and
dichloromethane, the organics were dried and purified by
chromatography (EtOAc) to give the sub-title compound as a white
solid (3.3 g).
[0143] .delta. .sup.1H.sub.DMSO 1.29(3H, S), 3.67 (1H, d), 3.76
(1H, d), 4.09 (1H, d), 4.15 (1H, d), 7.86 (4H, s), 5.24 (1H,s).
c) 2-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-benzoic
acid methyl ester
[0144] Prepared from a solution of the product of part b) (3.3. g)
in methanol (25 ml) which was treated with triethylamine (3.4 ml)
and heated under nitrogen at reflux for 1 hour. The mixture was
concentrated to dryness and purified by chromatography eluting with
a gradient from dichloromethane to 5% methanol in dichloromethane.
The chiral purity of the product was enhanced by recrystallising
twice from acetonitrile to give the sub-title compound as a white
solid (1.92 g).
[0145] HPLC: (9010THIP.M) 50 mm chiracel AD column, ee >99%.
[0146] .delta. .sup.1H.sub.CDCl3 1.52 (3H, s), 3.59 (1H, d), 3.81
(1H, d), 3.88 (1H, d), 4.04 (1H, s), 4.34 (1H, d), 3.92 (3H, s),
7.45 (1H, d), 7.49 (1H, t), 7.62 (1H, t), 8.00 (1H, d).
d) (4S)-4-Methyl-4-isoxazolidinol hydrochloride
[0147] Prepared from a solution of the product of part c) (4.9 g)
in 2 N hydrochloric acid (30 ml) which was heated under nitrogen at
reflux for 4 hours. After cooling the precipitate was removed by
filtration and the liquors concentrated to dryness under vacuo. The
residue was triturated with acetonitrile to give the sub-title
compound as a white solid (1.79 g).
[0148] .delta. .sup.1H.sub.DMSO 1.42 (3H, s), 3.29 (1H, d), 3.41
(1H, dD), 3.87 (1H, d), 4.05 (1H, dd).
e)
6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-1--
(2-methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid methyl ester
[0149] To a solution of
6-(bromomethyl)-1,2,3,4-tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxo--
thieno[2,3-d]pyrimidine-5-carboxylic acid methyl ester (1.0 g) in
chloroform (25 ml) was added zinc acetylacetonate hydrate (0.73 g)
and the mixture heated at reflux for 30 minutes. After cooling the
mixture was stirred vigorously with saturated sodium bicarbonate,
the organics were then collected and treated with 35% aqueous
hydrazine (1.0 ml) and stirred at ambient temperature for 16 hours.
The reaction mixture was washed with water and purified by
chromatography (ethyl acetate) to afford the sub-title compound as
a white solid (1.04 g).
[0150] .delta. .sup.1H.sub.CDCl3 0.93 (6H, d), 2.21-2.26 (1H, m),
2.21 (6H, s), 3.39 (3H, s), 3.68 (2H, d), 3.90 (2H, s), 3.96 (3H,
s).
f)
6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-1--
(2-methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid monosodium salt
[0151] Prepared from a solution of the product of step e) (19.0 g)
and sodium hydroxide (2.52 g) in THF (400 ml), water (35 ml) and
methanol (60 ml). After stirring at ambient temperature for 24
hours the precipitate was filtered off and washed with cold THF to
give the sub-title compound as a white solid (17.2 g).
[0152] .delta. .sup.1H.sub.D2O 0.90 (6H, d), 2.18 (6H, s), 2.20
(1H, non), 3.34 (3H, s), 3.72-3.77 (2H, d), 3.89 (2H, s).
g)
(4S)-2-[[6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3--
methyl-1-(2-methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]--
4-methyl-4-isoxazolidinol
[0153] A suspension of the product of step f) (200 mg), the product
of step d) (81 mg) and Pybrop (332 mg) in dichloromethane (10 ml)
was treated with triethylamine (0.20 ml) and the mixture stirred at
ambient temperature for 16 hours.
[0154] The reaction mixture was then purified by both normal phase
(0% to 10% methanol in dichloromethane) and reverse phase (5% to
95% methanol in 0.1% aqueous ammonium acetate) chromatography to
give the title compound as a white solid (90 mg).
[0155] .delta. .sup.1H.sub.DMSO 130.degree. C., 0.90 (6H, d), 1.41
(3H, s), 2.08 (6H, s), 2.18 (1H, non), 3.23 (3H, s), 3.67 (2H, d),
3.59-3.72 (3H, m), 3.77-3.82 (1H,m), 3.78 (2H, s), 4.92 (1H, s),
11.67 (1H, s).
EXAMPLE 2
(S)-2-[[6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-meth-
yl-1-(2-methylethyl)-2,4-dioxo-thienol[2,3-d]pyrimidin-5-yl]carbonyl]-4-me-
thyl-4-isoxazolidinol
##STR00022##
[0156] a)
6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-me-
thyl-1-(2-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid methyl ester
[0157] Prepared as example 1 step e) using
6-(bromomethyl)-1,2,3,4-tetrahydro-3-methyl-1-(2-methylethyl)-2,4-dioxo-t-
hieno[2,3-d]pyrimidine-5-carboxylic acid methyl ester.
[0158] .delta. .sup.1H.sub.CDCl3 1.53 (6H, d), 2.21 (6H, s), 3.36
(3H, s), 3.89 (2H, s), 3.96 (3H, s), 4.47 (1H,s).
b)
6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-1--
(2-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid
monosodium salt
[0159] Prepared using the method of example 1 step f) and the
product of step a).
[0160] .delta. .sup.1H.sub.DMSO 1.44 (6H, d), 2.10 (6H, s), 3.17
(3H, s), 3.72 (2H, s), 4.32 (1H, s).
c)
(4S)-2-[[6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3--
methyl-1-(2-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-
-methyl-4-isoxazolidinol
[0161] Prepared using the method of example 1 step g) using the
product of step b and example 1 step d).
[0162] .delta. .sup.1H.sub.DMSO 130.degree. C., 1.41 (3H, s), 1.46
(6H, d), 2.09 (6H, s), 3.20 (3H, s), 3.60-3.72 (3H, m), 3.78-3.82
(1H,m), 3.77 (2H, s), 4.46 (1H, sep), 4.94 (1H, s), 11.71 (1H,
s).
EXAMPLE 3
1-Cyclopropyl-6-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-5-[[(4S)-4-hydroxy--
4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-thienol[2,3-d]pyrimidine-2,4(-
1H,3H)-dione
##STR00023##
[0163] a) 2-(Cyclopropylamino)-5-methyl-3,4-thiophenedicarboxylic
acid, 3-ethyl 4-methyl ester
[0164] To a solution of (triphenylphosphoranylidene)-acetic acid
ethyl ester (15 g) in anhydrous tetrahydrofuran (100 ml) was added
isothiocyanato-cyclopropane (4.4 g) and the mixture was refluxed
under a nitrogen atmosphere for 20 hours. After allowing to cool to
ambient temperature the reaction mixture was cooled to -78.degree.
C. and then a solution of 3-bromo-2-oxo-butanoic acid methyl ester
(8.7 g) in anhydrous tetrahydrofuran (10 ml) was added. The
resulting mixture was allowed to warm to ambient temperature and
then refluxed for 20 hours, then ambient temperature for 2 days.
The reaction was poured into water and extracted with diethyl
ether. The collected organic extract was dried over magnesium
sulfate, filtered and evaporated under reduced pressure. The
residue was purified by column chromatography over silica, eluting
with i-hexane/ethyl acetate (95:5) then triturated with
i-hexane/diethyl ether (8:2) to give the sub-title compound as a
solid (7.5 g).
[0165] .delta. .sup.1H.sub.CDCl3 0.66 (2H, m), 0.75 (2H, m), 1.26
(3H, t), 2.27 (3H, s), 2.56 (1H, m), 3.83 (3H, s), 4.08 (2H,
quartet), 7.55 (1H, bs).
b)
1-Cyclopropyl-1,2,3,4-tetrahydro-6-methyl-2,4-dioxo-thieno[2,3-d]pyrimi-
dine-5-carboxylic acid, methyl ester
[0166] To a suspension of silver isocyanate (4.4 g) in anhydrous
toluene (30 ml) was added acetyl chloride (1.8 ml) dropwise over 5
minutes and the resulting mixture was stirred under a nitrogen
atmosphere at ambient temperature for 35 minutes. A solution of the
product of part a) (7.5 g) in anhydrous toluene (5 ml) was then
added and the mixture was stirred for 20 hours at ambient
temperature. The reaction was diluted with diethyl ether and the
precipitate was filtered. The resulting filtrate was washed with
sodium bicarbonate solution, dried over magnesium sulfate, filtered
and evaporated under reduced pressure. The resulting oil (9 g) was
treated with sodium methoxide solution (21 ml of a 25 wt % solution
in methanol) and the reaction was stirred under a nitrogen
atmosphere at ambient temperature for 20 hours. The mixture was
evaporated under reduced pressure and the resulting oil was
partitioned between ethyl acetate and water. The water layer was
separated and filtered to give the sub-title compound as a solid
(3.16 g).
[0167] MS (ESI) 281 [M+H].sup.+.
[0168] .delta. .sup.1H.sub.DMSO 0.96 (2H, m), 1.06 (2H, m), 2.38
(3H, s), 3.01 (1H, m), 3.78 (3H, s), 11.26 (1H, bs).
c)
1-Cyclopropyl-1,2,3,4-tetrahydro-3,6-dimethyl-2,4-dioxo-thieno[2,3-d]py-
rimidine-5-carboxylic acid, methyl ester
[0169] To a solution of the product of part b) (3.15 g) in
anhydrous dimethylformamide (40 ml) was added potassium carbonate
(1.9 g) and methyl iodide (0.84 ml). The mixture was stirred under
a nitrogen atmosphere at ambient temperature for 3 days. The
mixture was poured into water and the resulting solid was collected
by filtration to give the sub-title compound as a solid (2.8
g).
[0170] MS (ESI) 295 [M+H].sup.+.
[0171] .delta. .sup.1H.sub.DMSO 1.01 (2H, m), 1.05 (2H, m), 2.39
(3H, s), 3.07 (1H, m), 3.18 (3H, s), 3.80 (3H, s).
d)
6-(Bromomethyl)-1-cyclopropyl-1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-thi-
eno[2,3-d]pyrimidine-5-carboxylic acid, methyl ester
[0172] To a suspension of the product of part c) (2.8 g) in ethyl
acetate (50 ml) was added N-bromosuccinimide (1.9 g) and
azobis-isobutyronitrile (0.1 g). The resulting mixture was refluxed
under a nitrogen atmosphere for 2 hours then allowed to cool. This
mixture was washed successively with cold 0.5 M sodium hydroxide
solution then water, dried over magnesium sulfate, filtered and
evaporated under reduced pressure. The resulting solid was
triturated from cold diethyl ether to give the sub-title compound
as a solid (2.8 g).
[0173] .delta. .sup.1H.sub.CDCl3 1.10 (2H, m), 1.24 (2H, m), 3.03
(1H, m), 3.37 (3H, s), 3.99 (3H, s), 4.68 (2H, s).
e)
1-Cyclopropyl-6-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahyd-
ro-3-methyl-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid,
methyl ester
[0174] Prepared from the product of part d) following the procedure
of example 1, part e) to give the sub-title compound as a
solid.
[0175] MS (ESI) 389 [M+H].sup.+.
[0176] .delta. .sup.1H.sub.DMSO 0.93 (2H, m), 1.04 (2H, m), 2.07
(6H, m), 3.02 (1H, m), 3.17 (3H, s), 3.78 (3H, s), 3.81 (2H, s),
12.12 (1H, bs).
f)
1-Cyclopropyl-6-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahyd-
ro-3-methyl-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid,
monosodium salt
[0177] Prepared from the product of part e) following the procedure
of example 1, part f) to give the sub-title compound as a
solid.
[0178] MS (ESI) 375 [M+H].sup.+.
[0179] .delta. .sup.1H.sub.DMSO 0.84 (2H, m), 1.02 (2H, m), 2.06
(6H, s), 2.94 (1H, m), 3.17 (3H, s), 3.75 (2H, s), 11.98 (1H,
bs).
g)
1-Cyclopropyl-6-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-5-[[(4S)-4-hydro-
xy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-thieno[2,3-d]pyrimidine-2,-
4(1H,3H)-dione
[0180] Prepared from the product of part f) following the procedure
of example 1, part g) to give the title compound as a solid.
[0181] MS (ESI) 460 [M+H].sup.+.
[0182] .delta. .sup.1H.sub.DMSO 0.93 (2H, m), 1.03 (2H, m),
1.37-1.42 (3H, m), 2.08 (6H, bs), 3.02 (1H, m), 3.15 (3H, m),
3.58-3.80 (6H, m), 5.41 (1H, br s).
EXAMPLE 4
(S)-2-[[6-[(1H-1,2,3-Benzotriazol-1-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-
-1-(1-methylethyl)-2,4-dioxo-thienol[2,3-d]pyrimidin-5-yl]carbonyl]-4-meth-
yl-4-isoxazolidinol
##STR00024##
[0184] Prepared by the method of example 1 part g using
6-[(1H-1,2,3-Benzotriazol-1-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-m-
ethylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid
(0.15 g) to give a foam (0.042 g).
[0185] .delta. .sup.1H.sub.CDCl3 1.51 (9H, m inc H.sub.2O), 3.34
(3H, s), 3.47 (1H, d), 3.82 (1H, d), 3.97 (1H, d), 4.52 (1H, bm),
4.54 (1H, d), 5.34 (1H,s), 6.00 (2H, dd), 7.38 (1H, t), 7.49 (1H,
t).
EXAMPLE 5
(S)-2-[[6-[(4,5-Dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,4-tetrahy-
dro-1-ethyl-3-methyl-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-met-
hyl-4-isoxazolidinol
##STR00025##
[0187] Prepared by the method of example 1 part g using
6-[(4,5-dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,4-tetrahydro-1-e-
thyl-3-methyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid
to give the title compound (0.094 g, mp: 130-133.degree. C.).
[0188] .delta. .sup.1H.sub.CDCl3 1.38 (3H, t), 1.52 (3H, s), 2.40
(3H, s), 3.39 (3H, s), 3.43 (1H, d), 3.38 (1H, d), 3.96 (1H, d),
4.00 (2H, m), 4.46 (1H, d), 5.23 (2H, dd), 5.27 (1H, s).
EXAMPLE 6
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(2-methy-
lpropyl)-6-(1H-pyrrolol[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-2-
,4-(1H,3H)-dione
##STR00026##
[0189] a)
1,2,3,4-Tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxo-6-(1H-p-
yrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-5-carboxylic
acid methyl ester
[0190] To a solution of 7-azaindole (0.78 g) in anhydrous THF (30
ml) was added 2.5 M n-BuLi in hexanes (2.6 ml) dropwise at
10.degree. C. under nitrogen. After stirring the mixture for 15
minutes 1.0 M zinc chloride in ether (6.61 ml) was added and the
mixture stirred at room temperature for 2 hours. The solvent was
removed in vacuo and the residue diluted with anhydrous toluene (20
ml) then a solution of
6-(bromomethyl)-1,2,3,4-tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxo--
thieno[2,3-d]pyrimidine-5-carboxylic acid methyl ester (2.0 g) in
anhydrous toluene (10 ml) and a catalytic amount of potassium
iodide were added and the reaction mixture stirred under nitrogen
for 48 hours. The solvent was decanted, diluted with water and
extracted with ethyl acetate, the organic extracts washed with
water, dried over anhydrous magnesium sulfate, filtered and
evaporated under reduced pressure. The residue was purified by
column chromatography over silica, eluting with i-hexane/ethyl
acetate (1:1) to give the sub-title compound (1.37 g).
[0191] MS (ESI) 427 [M+H].sup.+.
b)
1,2,3,4-Tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxo-6-(1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-5-carboxylic
acid
[0192] To a solution of the product of part a) in THF (15 ml) and
methanol (7.5 ml) was added 1N sodium hydroxide (7.5 ml) and the
mixture stirred under nitrogen for 18 hours. It was acidified with
2.5 N hydrochloric acid and extracted with dichloromethane, the
organic extracts were washed with water, dried over anhydrous
magnesium sulfate, filtered and evaporated under reduced pressure
to give the sub-title compound as a solid (1.22 g)
[0193] MS (ESI) 413 [M+H].sup.+.
c)
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(2-me-
thylpropyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-
-2,4-(1H,3H)-dione
[0194] Prepared from the product of part b) by the method of
example 1 part g) to give the title compound as a solid.
[0195] MS (APCI) 427 [M+H].sup.+.
[0196] .delta. .sup.1H.sub.DMSO 0.82-0.85 (6H, m), 1.33-1.45 (3H,
m), 2.04-2.12 (1H, m), 3.16-3.20 (3H, m), 3.37-3.99 (6H, m),
4.13-4.23 (2H, m), 5.45-5.48 (1H, m)<6.99-7.02 (1H, m),
7.42-7.43 (1H, m), 7.91-7.96 (1H, m), 8.18-8.19 (1H, m),
11.52-11.55 (1H, m).
EXAMPLE 7
(4S)-4-methyl-2-[[1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-6-(4-quin-
olinylmethyl)thieno[2,3-dipyrimidin-5-yl]carbonyl]-4-isoxazolidinol
##STR00027##
[0198] Prepared using the method of example 1 step g) using
1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-6-(4-quinolinylmethyl)-thi-
eno[2,3-d]pyrimidine-5-carboxylic acid sodium salt and the product
of example 1 step d).
[0199] .delta. .sup.1H.sub.DMSO 120.degree. C., 0.85 (3H, t), 1.39
(3H, s), 1.66 (2H, sex), 3.23 (3H, s), 3.63-3.87 (6H, m), 4.59 (2H,
s), 5.03 (1H, s), 7.42 (1H, s), 7.61 (1H, t), 7.74 (1H, t), 8.04
(1H, d), 8.23 (1H, d), 8.83 (1H, s).
EXAMPLE 8
(4S)-2-[[6-[(2,4-Dichloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-3-methyl--
1-(2-methylpropyl)-2,4-dioxo-thienol[2,3-d]pyrimidin-5-yl]carbonyl]-4-meth-
yl-4-isoxazolidinol
##STR00028##
[0200] a)
6-[(2,4-Dichloro-5-thiazolyl)hydroxymethyl]-1,2,3,4-tetrahydro-3-
-methyl-1-(2-methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid, ethyl ester
[0201] To a solution of ethyl
3-methyl-1-(2-methylpropyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyr-
imidine-5-carboxylate (1.5 g),
2,4-dichlorothiazole-5-carboxaldehyde (1.75 g) and DMPU (1.2 ml) in
THF (25 ml) at -78.degree. C., was added LDA (10 mmol). Acetic acid
(3 ml) was added and the mixture allowed to warm to ambient
temperature.
[0202] The mixture was then partitioned between ethyl acetate and
water, the organics were collected, dried over magnesium sulphate
and concentrated to dryness. The residue was purified by normal
phase chromatography (3:1 i-hexane:ethyl acetate) to give the
sub-title compound as a yellow foam (0.45 g).
[0203] .delta. .sup.1H.sub.CDCl3 0.98 (3H, d), 0.99 (3H, d), 1.40
(3H, t), 2.22-2.35 (1H, m), 3.40 (3H, s), 3.76 (1H, d), 3.81 (1H,
d), 4.40-4.47 (2H, m), 6.30 (1H, s).
b)
6-[(2,4-Dichloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-m-
ethylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid,
ethyl ester
[0204] A solution of the product from step a) (0.45 g) in
dichloromethane (2 ml) was treated with trifluoroacetic acid (2 ml)
and triethylsilane (1.5 ml). The solution was then heated at reflux
for 3 hours. The mixture was concentrated to dryness and the
residue purified by chromatography on SiO.sub.2 (4:1 i-hexane:ethyl
acetate) to give the sub-title compound as a yellow oil (294
mg).
[0205] .delta. .sup.1H.sub.CDCl3 0.98 (6H, d), 1.42 (3H, t), 2.27
(1H, non), 3.39 (3H, s), 3.75 (2H, 4.24 (2H, s), 4.46 (2H, q).
c)
6-[(2,4-Dichloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-m-
ethylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid
sodium salt
[0206] Prepared by the method of example 1 step f) using the
product of step b).
[0207] .delta. .sup.1H.sub.DMSO 0.92 (6H, d), 2.18 (1H, non), 3.27
(3H, s), 3.75 (2H, d), 4.50 (2H, s).
d)
(4S)-2-[[6-[(2,4-Dichloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-3-meth-
yl-1-(2-methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-me-
thyl-4-isoxazolidinol
[0208] Prepared using the method of example 1 step g) using the
product of step c) and the product of example 1 step d).
[0209] .delta. .sup.1H.sub.DMSO 120.degree. C., 0.93 (6H, d), 1.40
(3H, s), 2.22 (1H, non), 3.23 (3H, s), 3.65-3.81 (6H, m), 4.25 (2H,
s), 5.02 (1H, s).
EXAMPLE 9
(4S)-2-[[6-[(3-Bromo-2-thienyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-me-
thylpropyl)-2,4-dioxo-thienol[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-is-
oxazolidinol
##STR00029##
[0210] a)
6-[(3-Bromo-2-thienyl)hydroxymethyl]-1,2,3,4-tetrahydro-3-methyl-
-1-(2-methylpropyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid ethyl ester
[0211] Prepared according to the method of example 8 step a) using
3-bromo-2-thiophenecarboxaldehyde.
[0212] .delta. .sup.1H.sub.CDCl3 0.96 (3H, d), 0.97 (3H, d), 1.38
(3H, t), 2.27 (1H, non), 3.39 (3H, s), 3.66 (1H, d), 3.71 (1H, dd),
3.79 (1H, dd), 4.38-4.46 (2H, m), 6.38 (1H, d), 6.98 (1H, d), 7.35
(1H, d).
b)
6-[(3-Bromo-2-thienyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-methylpr-
opyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid ethyl
ester
[0213] Prepared according to the method of example 8 step b) using
the product of step a).
[0214] .delta. .sup.1H.sub.CDCl3 0.96 (6H, d), 1.42 (3H, t), 2.25
(1H, non), 3.39 (3H, s), 3.72 (2H, d), 4.32 (2H, s), 4.47 (2H, q),
6.96 (1H, d), 7.23 (1H, d).
c.)
6-[(3-Bromo-2-thienyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-methylp-
ropyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid sodium
salt
[0215] Prepared by the method of example 1 step f) using the
product of step b).
[0216] .delta. .sup.1H.sub.DMSO 0.87 (6H, d), 2.16 (1H, non), 3.21
(3H, s), 3.66 (2H, d), 4.20 (2H, s), 7.04 (1H, d), 7.53 (1H,
d).
d.)
(4S)-2-[[6-[(3-Bromo-2-thienyl))methyl]-1,2,3,4-tetrahydro-3-methyl-1--
(2-methylpropyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-
-isoxazolidinol
[0217] Prepared using the method of example 1 step g) using the
product of step c) and the product of example 1 step d).
[0218] .delta. .sup.1H.sub.DMSO 120.degree. C., 0.91 (6H, d), 1.40
(3H, s), 2.19 (1H, non), 3.23 (3H, s), 3.65-3.81 (6H, m), 4.24 (2H,
s), 5.00 (1H, s), 7.01 (1H,d), 7.51 (1H, d).
EXAMPLE 10
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methy-
lethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,-
3-d]pyrimidine-2,4(1H,3H)-dione
##STR00030##
[0219] a)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-6-[[5-methyl-3-(tr-
ifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,4-dioxo-thieno[2,3-d]pyrimidine-5-
-carboxylic acid
[0220] To a suspension of
6-(bromomethyl)-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-t-
hieno[2,3-d]pyrimidine-5-carboxylic acid methyl ester (1.4 g) in
chloroform (15 ml) was added zinc acetate (0.82 g) and
1,1,1-trifluoro-2,4-pentanedione (0.55 ml). The mixture was
refluxed for 3 hours then allowed to cool, diluted with
dichloromethane and washed with sodium bicarbonate solution. The
organic layer was separated and the aqueous was extracted with
dichloromethane. The combined organic extracts were dried over
magnesium sulfate and evaporated under reduced pressure. The
resulting oil was dissolved in ethanol (15 ml) and treated with
hydrazine monohydrate (0.24 ml) and the reaction was stirred at
ambient temperature for 20 hours. The reaction was evaporated under
reduced pressure, dissolved in acetonitrile (10 ml), treated with 2
M HCl solution (10 ml) and refluxed for 20 hours. The resulting
solid was collected by filtration, washing with water and then
diethyl ether to give the sub-title compound as a solid (0.68
g).
[0221] MS (ESI) 431 [M+H].sup.+.
[0222] .delta. .sup.1H.sub.DMSO 1.44 (6H, d), 2.22 (3H, s), 3.23
(3H, s), 4.20 (2H, s), 4.36 (1H, bs), 13.44 (1H, bs).
b)
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-me-
thylethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno-
[2,3-d]pyrimidine-2,4(1H,3H)-dione
[0223] To a suspension of the product of part a) (0.2 g) in
anhydrous dimethylformamide (3 ml), was added triethylamine (0.29
ml), 1-hydroxybenzotriazole (0.078 g) followed by diethyl
chlorophosphate (0.075 ml) and the mixture stirred at ambient
temperature under nitrogen for thours 15 minutes.
(4S)-4-Methyl-4-isoxazolidinol hydrochloride (0.07 g) was added and
the reaction mixture was stirred at ambient temperature for 20
hours. It was concentrated under reduced pressure, diluted with
saturated sodium bicarbonate solution and extracted with
dichloromethane. The organic extracts were dried over anhydrous
magnesium sulfate, filtered and evaporated under reduced pressure.
The residue was purified by column chromatography over silica,
eluting with dichloromethane/methanol (98:2) followed by
dichloromethane/methanol (96:4) to give the title compound as a
solid (0.11 g).
[0224] MS (ESI) 516 [M+H].sup.+.
[0225] .delta. .sup.1H.sub.DMSO 1.24-1.38 (3H, m), 1.44 (6H, s),
2.20 (3H, s), 3.18 (3H, s), 3.62 (2H, m), 3.75 (2H, m), 3.82 (2H,
m), 4.37 (1H, bs), 5.23-5.42 (1H, m), 13.38 (1H, bs).
EXAMPLE 11
6-[[3,5-Dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-5-[[(4S)-4-hydrox-
y-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thienol[2,-
3-d]pyrimidine-2,4-(1H,3H)-dione
##STR00031##
[0226] a)
6-[[3,5-Dimethyl-1-(2-pyridyl)-1H-pyrazol-4-yl]methyl-1,2,3,4-te-
trahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidine-5-car-
boxylic acid methyl ester
[0227] Prepared from
6-(bromomethyl)-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxoth-
ieno[2,3-d]pyrimidine-5-carboxylic acid methyl ester, zinc
acetylacetonate hydrate and 2-hydrazinopyridine by the method of
example 1 part e) to give the sub-title compound.
[0228] MS (ESI) 468 [M+H].sup.+.
[0229] .delta. .sup.1H.sub.DMSO 1.45 (6H, d), 2.16 (3H, s), 2.56
(3H, s), 3.18 (3H, s), 3.78 (3H, s), 3.95 (2H, s), 4.40 (1H, s,
br), 7.31-7.34 (1H, m), 7.79-7.82 (1H, m), 7.93-7.97 (1H, m),
8.45-8.47 (1H, m).
b)
6-[[3,5-Dimethyl-1-(2-pyridyl)-1H-pyrazol-4-yl]methyl-1,2,3,4-tetrahydr-
o-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidine-5-carboxylic
acid
[0230] Prepared from the product of part a) by the method of
example 6 part b) to give the sub-title compound as a solid.
[0231] MS (ESI) 454 [M+H].sup.+.
c)
6-[[3,5-Dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-5-[[(4S)-4-hyd-
roxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[-
2,3-d]pyrimidine-2,4-(1H,3H)-dione
[0232] Prepared from the product of part b) by the method of
example 1 part g) to give the title compound as a solid.
[0233] MS (APCI) 539 [M+H].sup.+.
[0234] .delta. .sup.1H.sub.DMSO 1.23-1.46 (9H, m), 2.17-2.18 (3H,
m), 2.55-2.58 (3H, m), 3.18-3.19 (3H, m), 3.57-3.94 (6H, m), 4.38
(1H, s, br), 5.42 (1H, d), 7.30-7.34 (1H, m), 7.81 (1H, d),
7.93-7.97 (1H, m), 8.45-8.47 (1H, m).
EXAMPLE 12
5-[[(4S)-4-Hydroxy-4-methyl-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methyle-
thyl)-6-(1H-pyrrolo
[2,3-b]pyridin-3-ylmethyl)-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00032##
[0235] a)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-(1H-py-
rrolo[2,3-b]pyridin-3-ylmethyl)-thieno[2,3-d]pyrimidine-5-carboxylic
acid, sodium salt
[0236] Prepared from
6-(bromomethyl)-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-t-
hieno[2,3-d]pyrimidine-5-carboxylic acid, methyl ester (0.45 g,
1.20 mmol) and 7-azaindole (0.17 g, 1.44 mmol) using the method of
example 6 part a). The residue was purified by silica
chromatography eluting with a gradient from 50% ethyl acetate in
isohexane to 100% ethyl acetate to give a colourless oil (0.27 g).
0.1 g of this oil was dissolved in THF (2 mL) and treated with 1 M
sodium hydroxide solution (0.8 mL) and 0.5 mL of methanol. After 5
hours, a precipitate appeared which was filtered off, washed with
THF then with ether to give the sub-title compound as a pale yellow
solid.
[0237] MS (ES) 399 [M+H].sup.+.
b)
5-[[(4S)-4-Hydroxy-4-methylisoxazolidinyl]carbonyl]-3-methyl-1-(1-methy-
lethyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thieno[2,3-d]pyrimidine-2,-
4(1H,3H)-dione
[0238] Prepared from the product of example 12 part a) (0.2 g) and
the product of example 1 part d) (0.08 g) using the method of
example 1 part g). The residue was purified by reverse phase HPLC
(95% to 50% aqueous 0.1% ammonium acetate in acetonitrile) to give
the title compound as a white foam (0.1 g).
[0239] MS (APCI) 484.1642 [M+H].sup.+.
[0240] .delta. .sup.1H.sub.DMSO 1.23-1.44 (9H, d+s), 3.18 (3H, s),
3.4-4.4 (7H, range of ppm), 5.45 (1H, bs), 7-7.06 (1H, m), 7.43
(1H, s), 7.93-7.99 (1H, m), 8.18-8.20 (1H, d), 11.53 (1H, s).
EXAMPLE 13
(4S)-2-[[6-[[3,5-Dimethyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4--
tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thienol[2,3-d]pyrimidin-5--
yl]carbonyl]-4-methyl-4-isoxazolidinol
##STR00033##
[0241] a)
6-[[3,5-Dimethyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-
-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-
-carboxylic acid ethyl ester
[0242] To a solution of the product of example 2 step a) (500 mg)
in acetonitrile (5 ml) was added 4-chloropyridine hydrochloride
(550 mg). The mixture was then microwave irradiated at 100 W and
140.degree. C. for 20 minutes. The mixture was concentrated to
dryness and purified by chromatography on SiO.sub.2 (EtOAc to 20%
MeOH in EtOAc) to give the sub-title compound as a white solid (200
mg).
[0243] .delta. .sup.1H.sub.CDCl3 1.55 (6H, d), 2.27 (3H, s), 2.41
(3H, s), 3.37 (3H, s), 3.94 (3H, s), 3.96 (2H, s), 4.46 (1H, s),
7.49 (2H, dd), 8.69 (2H, dd).
b)
6-[[3,5-Dimethyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrah-
ydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carbox-
ylic acid sodium salt
[0244] Prepared by the method of example 1 step f) using the
product of step a).
[0245] .delta. .sup.1H.sub.DMSO 1.45 (6H, d), 2.21 (3H, s), 2.46
(3H, s), 3.17 (3H, s), 3.85 (2H, s), 4.32 (1H, s), 7.62 (2H, dd),
8.63 (2H, dd).
c)
(4S)-2-[[6-[[3,5-Dimethyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3-
,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidin--
5-yl]carbonyl]-4-methyl-4-isoxazolidinol
[0246] Prepared using the method of example 1 step g) using the
product of step b) and the product of example 1 step d).
[0247] .delta. .sup.1H.sub.DMSO 120.degree. C., 1.40 (3H, s), 1.48
(6H, d), 2.18 (3H, s), 2.39 (3H, s), 3.21 (3H, s), 3.65 (1H, S),
3.70 (2H, d), 3.80 (1H, d), 3.89 (2H, s), 4.47 (1H, sep), 7.55 (2H,
d), 8.62 (2H, d).
EXAMPLE 14
(4S)-2-[[6-[[3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,-
4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thienol[2,3-d]pyrimidin--
5-yl]carbonyl]-4-methyl-4-isoxazolidinol
##STR00034##
[0248] a)
6-[[3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3-
,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-
-5-carboxylic acid ethyl ester
[0249] Prepared according to the method of example 13 step a) using
2-chloropyrimidine.
[0250] .delta. .sup.1H.sub.CDCl3 1.52 (6H, d), 2.31 (3H, s), 2.65
(3H, s), 3.37 (3H, s), 3.98 (5H, s), 4.45 (1H, s), 7.19 (1H, t),
8.78 (2H, d).
b)
6-[[3,5-Dimethyl-1-(4-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetr-
ahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carb-
oxylic acid sodium salt
[0251] Prepared by the method of example 1 step f) using the
product of step a).
[0252] .delta. .sup.1H.sub.D2O 1.49 (6H, s), 2.27 (3H, s), 2.54
(3H, s), 3.31 (3H, s), 3.98 (1H, s), 4.45 (1H, s), 7.51 (1H, s),
8.86 (2H, s).
c)
(4S)-2-[[6-[[3,5-Dimethyl-1-(4-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2-
,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidi-
n-5-yl]carbonyl]-4-methyl-4-isoxazolidinol
[0253] Prepared by the method of example 1 step f) using the
product of step b).
[0254] .delta. .sup.1H.sub.DMSO 120.degree. C. 1.40 (3H, s), 1.47
(6H, d), 2.18 (3H, s), 2.52 (3H, s), 3.21 (3H, s), 3.63-3.72 (3H,
m), 3.78-3.83 (1H, m), 4.46 (1H, sep), 4.98 (1H, s), 7.38 (1H, t),
8.81 (2H, d).
EXAMPLE 15
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methy-
lethyl)-6-[(1-phenyl-1H-pyrazol-4-yl)methyl]-thieno[2,3-d]pyrimidine-2,4-(-
1H,3H)-dione
##STR00035##
[0255] a)
1,2,3,4-Tetrahydro-6-[hydroxy(1-phenyl-1H-pyrazol-4-yl)methyl]-3-
-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid ethyl ester
[0256] To a solution of
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrim-
idine-5-carboxylic acid ethyl ester (2.0 g),
1-phenyl-1H-pyrazole-4-carboxaldehyde (1.39 g) and
1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (1.63 ml) in
anhydrous THF (35 ml) was added a 2.0 M solution of LDA (3.72 ml)
at -78.degree. C. under nitrogen and the resulting mixture stirred
for 3 hours. Glacial acetic acid (1.5 ml) was added, the mixture
allowed to warm to room temperature, diluted with water and
extracted with ethyl acetate, the organic extracts washed with
water, dried over anhydrous magnesium sulfate, filtered and
evaporated under reduced pressure. The residue was purified by
column chromatography over silica, eluting with i-hexane/ethyl
acetate (4:1) followed by i-hexane/ethyl acetate (1:1) to give the
sub-title compound (2.32 g).
[0257] MS (ESI) 469 [M+H].sup.+.
b)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[(1-phenyl-1H-
-pyrazol-4-yl)methyl]-thieno[2,3-d]pyrimidine-5-carboxylic acid
ethyl ester
[0258] A solution of the product of part a) (2.32 g),
trifluoroacetic acid (10 ml) and triethylsilane (5 ml) in
dichloromethane (5 ml) was heated at 40.degree. C. under nitrogen
for 24 hours. The solvent was removed in vacuo, the residue diluted
with aqueous sodium bicarbonate solution and extracted with
dichloromethane, the organic extracts washed with water, dried over
anhydrous magnesium sulfate, filtered and evaporated under reduced
pressure. The residue was purified by column chromatography over
silica, eluting with i-hexane/ethyl acetate (9:1) followed by
i-hexane/ethyl acetate (4:1) to give the sub-title compound (2.11
g).
[0259] MS (ESI) 453 [M+H].sup.+.
[0260] .delta. .sup.1H.sub.DMSO 1.26 (3H, t), 1.47 (6H, d), 3.19
(3H, s), 4.04 (2H, s), 4.29 (2H, q), 4.37 (1H, s, br), 7.28-7.32
(1H, m), 7.47-7.51 (2H, m), 7.65 (1H, s), 7.78-7.81 (2H, m), 8.40
(1H, s).
c)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[(1-phenyl-1H-
-pyrazol-4-yl)methyl]-thieno[2,3-d]pyrimidine-5-carboxylic acid
[0261] Prepared from the product of part b) by the method of
example 6 part b) to give the sub-title compound as a solid.
[0262] MS (ESI) 425 [M+H].sup.+.
d)
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-me-
thylethyl)-6-[(1-phenyl-1H-pyrazol-4-yl)methyl]thieno[2,3-d]pyrimidine-2,4-
-(1H,3H)-dione
[0263] To a solution of the product of part c) (0.5 g), the product
of example 1 part d) (0.18 g), and 1-hydroxybenzotriazole (0.36 g)
in dichloromethane (10 ml) was added triethylamine (0.36 ml) and
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.45
g) and the mixture stirred at ambient temperature under nitrogen
for 18 hours. It was diluted with water and extracted with
dichloromethane, the organic extracts were washed successively with
1.0N sodium hydroxide and water, dried over anhydrous magnesium
sulfate, filtered and evaporated under reduced pressure. The
residue was purified by column chromatography over silica, eluting
with ethyl acetate/methanol (99:1) followed by ethyl
acetate/methanol (49:1) to give the title compound as a solid (0.14
g).
[0264] MS (APCI) 496 [M+H].sup.+.
[0265] .delta. .sup.1H.sub.DMSO 1.46-1.52 (6H, m), 3.18-3.20 (3H,
m), 3.51-4.12 (6H, m), 4.41-4.54 (1H, m), 4.62-4.79 (1H, m),
5.48-5.56 (1H, m), 7.30 (1H, t), 7.49 (2H, t), 7.64-7.68 (1H, m),
7.79 (2H, d), 8.39 (1H, s).
EXAMPLE 16
6-[(8-Fluoroquinolin-4-yl)methyl]-5-{[(4S)-4-hydroxy-4-methylisoxazolidin--
2-yl]carbonyl}-1-isopropyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dion-
e
##STR00036##
[0266] a) 8-Fluoro-4-methyl quinoline
[0267] To a solution of 2-fluoroaniline (25 ml) in ethanol (185 ml)
was added concentrated hydrochloric acid (21 ml), iron (III)
chloride hexahydrate (111 g) and zinc (II) chloride (4.1 g) and the
resulting mixture was heated to 60.degree. C. Methyl vinyl ketone
(25 ml) was added dropwise over 45 minutes, then the mixture was
refluxed for 2 hours. The reaction mixture was allowed to cool then
evaporated under reduced pressure. The resulting oil was basified
to pH 12 with 2 M sodium hydroxide solution, filtered through
arbocel and then the aqueous was extracted with ethyl acetate
(.times.2). The combined organic extracts were dried over anhydrous
magnesium sulfate, filtered and evaporated under reduced pressure.
The residue was purified by column chromatography over silica,
eluting with i-hexane/diethyl ether (3:1) followed by
i-hexane/diethyl ether (2:1) to give the sub-title compound as a
solid (8.25 g).
[0268] MS (ESI) 162 [M+H].sup.+.
[0269] .delta. .sup.1H.sub.CDCl3 2.72 (3H, s), 7.28 (1H, m), 7.39
(1H, m), 7.49 (1H, m), 7.77 (1H, d), 8.83 (1H, d).
b) 8-Fluoro-4-quinolinecarboxaldehyde
[0270] To a solution of the product of part a) (8.25 g) in dioxane
(20 ml) at 70.degree. C. was added, dropwise over 20 minutes, a
solution of selenium dioxide in dioxane (15 ml) and water (5 ml).
The reaction mixture was refluxed for 2.5 hour. and then ambient
temperature for 20 hours. To the resulting mixture was added ethyl
acetate and the suspension was decanted from the solid selenium
metal. The organic layer was then evaporated under reduced pressure
and the residue was purified by column chromatography over silica,
eluting with DCM/diethyl ether (1:1) to give the sub-title compound
as a solid (3.61 g).
[0271] MS (ESI) 176 [M+H].sup.+.
[0272] .delta. .sup.1H.sub.CDCl3 7.54 (1H, m), 7.67 (1H, m), 7.83
(1H, d), 8.82 (1H, d), 9.26 (1H, d), 10.52 (1H, s).
c)
6-[(8-Fluoro-4-quinolinyl)hydroxymethyl]-1,2,3,4-tetrahydro-3-methyl-1--
(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid, ethyl ester
[0273] To a solution of
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrim-
idine-5-carboxylic acid, ethyl ester (1.5 g), the product of part
b) (1.2 g) and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone
(1.3 ml) in anhydrous THF (20 ml) was added a freshly prepared
solution of LDA (2.4ml of 2.5M n-BuLi, 0.92ml of diisopropylamine
in anhydrous THF (10 ml)) at -78.degree. C. under nitrogen and the
resulting mixture stirred for 1.5 hours. Glacial acetic acid (3 ml)
was added, the mixture allowed to warm to room temperature, diluted
with saturated sodium bicarbonate solution and extracted with DCM
(.times.2), the organic extracts were dried over anhydrous
magnesium sulfate, filtered and evaporated under reduced pressure.
The residue was purified by column chromatography over silica,
eluting with i-hexane/ethyl acetate (80:20) followed by
i-hexane/ethyl acetate (60:40) and then by i-hexane/ethyl acetate
(25:75) to give the sub-title compound as a solid (0.81 g).
[0274] MS (ESI) 472 [M+H].sup.+.
[0275] .delta. .sup.1H.sub.CDCl3 1.40 (3H, t), 1.46 (6H, d), 3.35
(3H, s), 3.76 (1H, d), 4.36 (1H, bs), 4.48 (2H, quartet), 6.74 (1H,
d), 7.44 (2H, m), 7.72 (1H, d), 7.93 (1H, d), 9.06 (1H, d).
d)
6-[(8-Fluoro-4-quinolinyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-meth-
ylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid ethyl
ester
[0276] To a degassed solution of the product of part c) (0.8 g) in
anhydrous THF (15 ml) under nitrogen was added triethylamine (0.85
ml) and trifluoroacetic anhydride (0.4 ml). The reaction mixture
was stirred at ambient temperature for 2 hours. 10% Palladium on
charcoal (0.1 g) was added to the mixture under nitrogen and then
hydrogenated at 4 bar, ambient temperature for 20 hours. The
mixture was filtered through a pad of celite under nitrogen,
washing with ethyl acetate and the filtrate was evaporated under
reduced pressure. The resulting oily solid was triturated with
diethyl ether:ethyl acetate 95:5, filtered under nitrogen, washed
with diethyl ether and dried in vacuo to give the sub-title
compound as a solid (0.42 g).
[0277] MS (ESI) 456 [M+H].sup.+.
[0278] .delta. .sup.1H.sub.CDCl3 1.37 (3H, t), 1.54 (6H, d), 3.37
(3H, s), 4.42 (2H, quartet), 4.45 (1H, bs), 4.60 (2H, s), 7.38 (1H,
d), 7.43 (1H, m), 7.56 (1H, m), 7.92 (1H, d), 8.95 (1H, d).
e)
6-[(8-Fluoro-4-quinolinyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-meth-
ylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid,
sodium salt
[0279] To a degassed solution of the product of part d) (0.42 g) in
THF (6 ml)/methanol (1 ml) under nitrogen was added 1 N sodium
hydroxide solution (1.4 ml) and the mixture was stirred at ambient
temperature for 72 hours. The reaction mixture was evaporated under
reduced pressure, azeotroped with diethyl ether (.times.2) and then
triturated with diethyl ether, filtered and dried in vacuo to give
the sub-title compound as a solid (0.36 g).
[0280] MS (ESI) 428 [M+H].sup.+.
[0281] .delta. .sup.1H.sub.DMSO 1.38 (6H, d), 4.25 (1H, bs), 4.56
(2H, s), 7.55 (2H, m), 7.63 (1H, d), 8.47 (1H, m), 8.86 (1H,
d).
f)
6-[(8-Fluoroquinolin-4-yl)methyl]-5-{[(4S)-4-hydroxy-4-methylisoxazolid-
in-2-yl]carbonyl}-1-isopropyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-d-
ione
[0282] To a suspension of the product of part e) (175 mg) in
dichloromethane (3 ml) was added 1-hydroxybenzotriazole (66 mg) and
the mixture was stirred at ambient temperature under nitrogen for
20 minutes. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride (95 mg) was added and the mixture was stirred for 1
hr. The product of example 1 part d) (70 mg) and triethylamine
(0.07 ml) were added and the mixture stirred at ambient temperature
under nitrogen for 72 hours. The mixture was diluted with water and
extracted with dichloromethane (.times.3), the combined organic
extracts were dried over anhydrous magnesium sulfate, filtered and
evaporated under reduced pressure. The residue was purified by
column chromatography over silica, eluting with
dichloromethane/methanol (98:2) and was further purified by reverse
phase HPLC (95% to 50% aqueous 0.1% ammonium acetate in
acetonitrile) to give the title compound as a white solid (45
mg).
[0283] MS (ESI) 513 [M+H].sup.+.
[0284] .delta. .sup.1H.sub.DMSO 1.16-1.35 (3H, m), 1.43 (6H, m),
3.19 (3H, m), 3.57-3.82 (4H, m), 4.37 (1H, bs), 4.60 (2H, m),
5.22-5.48 (1H, m), 7.61 (3H, m), 8.11 (1H, m), 8.91 (1H, d).
EXAMPLE 17
5-{[(4S)-4-Hydroxy-4-methylisoxazolidin-2-yl]carbonyl]-1-isopropyl-3-methy-
l-6-(4-pyrimidin-2-ylbenzyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00037##
[0285] a) 4-(2-Pyrimidinyl)-benzaldehyde
[0286] To a degassed suspension of 4-formylphenylboronic acid (100
mg), 2-bromopyrimidine (107 mg) and sodium carbonate (212 mg) in
acetonitrile (2 ml)/water (2 ml) was added freshly prepared
tetrakis(triphenylphosphine)palladium(0) (40 mg) and the mixture
was refluxed under nitrogen, for 20 hours. The cooled reaction
mixture was diluted with water and extracted with ethyl acetate
(.times.2). The combined organic extracts were dried over anhydrous
magnesium sulfate, filtered and evaporated under reduced pressure.
The residue was purified by column chromatography over silica,
eluting with iso-hexane/ethyl acetate (75:25) to afford the
sub-title compound as a solid (90 mg).
b)
1,2,3,4-Tetrahydro-6-[hydroxy[4-(2-pyrimidinyl)phenyl]methyl]-3-methyl--
1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid, ethyl ester
[0287] Prepared from the product of part a) by the method of
example 16 part c) to give the sub-title compound as a foam.
[0288] MS (ESI) 481 [M+H].sup.+.
[0289] .delta. .sup.1H.sub.CDCl3 1.36 (3H, t), 1.55 (6H, d), 3.36
(3H, s), 3.50 (1H, d), 4.39 (2H, quartet), 4.51 (1H, bs), 6.19 (1H,
d), 7.21 (1H, t), 7.60 (2H, d), 8.46 (2H, d), 8.82 (2H, d).
c)
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[[4-(2-pyrimi-
dinyl)phenyl]methyl]-thieno[2,3-d]pyrimidine-5-carboxylic acid,
ethyl ester
[0290] A solution of the product from step b) (1.37 g) in
dichloromethane (10 ml) was treated with trifluoroacetic acid (10
ml) and triethylsilane (10 ml). The solution was then heated at
reflux for 48 hours under nitrogen. The mixture was allowed to
cool, concentrated to dryness and azeotroped with dichloromethane.
The residue was disolved in dichloromethane and washed with
saturated sodium carbonate solution (.times.4) then water
(.times.1), dried over anhydrous magnesium sulfate, filtered and
evaporated under reduced pressure. The residue was stirred in
iso-hexane for 24 hours, filtered and washed with iso-hexane to
give a solid (800 mg).
[0291] To a rapidly stirred solution of the solid (800 mg) in
acetone (15 ml) was added, dropwise, a saturated solution of
potassium permanagnate in acetone (1 ml) until a dark brown
suspension was maintained. The mixture was stirred open to the air
at ambient temperature for 15 minutes. Further saturated potassium
permanaganate solution in acetone (0.5 ml) was added and the
mixture was stirred for 10 minutes (repeated twice more). The
resulting mixture was filtered through arbocel and the filtrate was
evaporated under reduced pressure. The arbocel was slurried in
acetone, filtered and combined with the above residue and
evaporated under reduced pressure. The residue was purified by
column chromatography over silica, eluting with iso-hexane/ethyl
acetate (1:1) to afford the sub-title compound as a solid (400
mg).
[0292] MS (ESI) 465 [M+H].sup.+.
[0293] .delta. .sup.1H.sub.CDCl3 1.38 (3H, t), 1.55 (6H, d), 3.37
(3H, s), 4.19 (2H, s), 4.46 (2H, quartet), 4.50 (1H, bs), 7.18 (1H,
t), 7.39 (2H, d), 8.42 (2H, d), 8.78 (2H, d).
d)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[[4-(2-pyrimi-
dinyl)phenyl]methyl]-thieno[2,3-d]pyrimidine-5-carboxylic acid,
monohydrochloride
[0294] To a suspension of the product of part c) (560 mg) in
acetonitrile (5 ml) was added 2 M hydrochloric acid solution (5 ml)
and the mixture was refluxed for 4 hours. The mixture was allowed
to cool and the solid was collected by filtration, washing with
water and dried in a vacuum oven at 50.degree. C. for 20 hours to
give the sub-title compound as a solid (440 mg).
[0295] MS (ESI) 437 [M+H].sup.+.
[0296] .delta. .sup.1H.sub.DMSO 1.45 (6H, d), 3.23 (3H, s), 4.35
(2H, s), 4.44 (1H, bs), 7.45 (3H, m), 8.36 (2H, d), 8.90 (2H,
d).
e)
5-{[(4S)-4-Hydroxy-4-methylisoxazolidin-2-yl]carbonyl}-1-isopropyl-3-me-
thyl-6-(4-pyrimidin-2-ylbenzyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
[0297] Prepared from the product of part d) by the method of
example 16 part f) to give the title compound as a solid.
[0298] MS (ESI) 522 [M+H].sup.+.
[0299] .delta. .sup.1H.sub.DMSO 1.33-1.38 (3H, m), 1.46 (6H, m),
3.19 (3H, s), 3.64-4.15 (6H, m), 4.44 (1H, bs), 5.45 (1H, bs), 7.44
(3H, m), 8.33(2H, d), 8.89 (2H, d).
EXAMPLE 18
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methy-
lethyl)-6-1(5-(2-pyridinyl)-2-thienyl)methyl]-thieno[2,3-d]pyrimidine-2,4--
(1H,3H)-dione
##STR00038##
[0300] a)
1,2,3,4-Tetrahydro-6-[hydroxy-[(5-(2-pyridinyl)-2-thienyl)methyl-
]-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxyli-
c acid ethyl ester
[0301] Prepared following the procedure of example 15 a) using
5-(2-pyridinyl)-2-thiophenecaboxaldehyde.
[0302] MS (ESI) 486 [M+H].sup.+.
[0303] .delta. .sup.1H.sub.DMSO 1.35 (3H, t), 1.58 (6H, d), 3.37
(3H, s), 3.42 (1H, d), 4.40 (2H, q), 4.55 (1H, b), 6.37 (1H, d),
7.07 (1H, d), 7.15 (1H, m), 7.45 (1H, d), 7.63 (1H, d), 7.69 (1H,
td), 8.55 (1H, m).
b)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[(5-(2-pyridi-
nyl)-2-thienyl)methyl]-thieno[2,3-d]pyrimidine-5-carboxylic acid
ethyl ester
[0304] Prepared from the product of part a) following the procedure
of example 15 part b).
[0305] MS (ESI) 470 [M+H].sup.+.
[0306] .delta. .sup.1H.sub.DMSO 1.40 (3H, t), 1.55 (6H, d), 3.37
(3H, s), 4.34 (2H, s), 4.4-4.5 (1H, b), 4.45 (2H, s, q), 6.94 (1H,
d), 7.14 (1H, m), 7.43 (1H, d), 7.61 (1H, d), 7.67 (1H, td), 8.54
(1H, d).
c)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[(5-(2-pyridi-
nyl)-2-thienyl)methyl]-thieno[2,3-d]pyrimidine-5-carboxylic
acid
[0307] Prepared from the product of part b) by the method of
example 6 part b) to give the sub-title compound as a solid.
[0308] MS (ESI) 442 [M+H].sup.+.
d)
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-me-
thylethyl)-6-[(5-(2-pyridinyl)-2-thienyl)methyl]thieno[2,3-d]pyrimidine-2,-
4-(1H,3H)-dione
[0309] Prepared from the product of part c) by the method of
example 15 part d)
[0310] MS (APCI) 540 [M+H].sup.+.
[0311] .delta. .sup.1H.sub.DMSO 1.48 (3H, s), 1.53 (6H, t), 2.32
(3H, s), 2.26 (3H, s), 3.35 (3H, s), 3.43 (1H, d), 3.86 (1H, d),
3.97 (2H, dd), 4.52 (2H, m), 5.41 (1H, s), 7.19 (1H, t), 8.77 (2H,
d).
EXAMPLE 19
6-[(1,3-Dimethyl-1H-5-pyrazolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-isox-
azolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-thieno[2,3-d]pyrimidine-2,-
4-(1H,3H)-dione
##STR00039##
[0312] a)
1,2,3,4-Tetrahydro-6-[(1,3-Dimethyl-1H-5-pyrazolyl)methyl]-3-met-
hyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid ethyl ester
[0313] Prepared following the procedure of example 15 a) using
1,3-dimethylpyrazole-5-carboxaldehyde.
[0314] MS (ESI) 421 [M+H].sup.+.
[0315] .delta. .sup.1H.sub.DMSO 1.33 (3H, t), 1.58 (6H, m), 2.24
(3H, s), 3.37 (3H, s), 3.77 (3H, s), 4.35 (2H, m), 4.56 (1H, b),
6.06 (1H, s), 6.13 (1H, d).
b)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[(,3-Dimethyl-
-1H-5-pyrazolyl)methyl]-thieno[2,3-d]pyrimidine-5-carboxylic acid
ethyl ester
[0316] Prepared from the product of part a) following the procedure
of example 15 part b).
[0317] MS (ESI) 405 [M+H].sup.+.
[0318] .delta. .sup.1H.sub.DMSO 1.39 (3H, t), 1.55 (6H, d), 2.24
(3H, s), 3.37 (3H, s), 3.72 (3H, s), 4.12 (2H, s), 4.43 (2H, q),
4.50 (1H, b), 5.94 (1H, s).
c)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[(1,3-Dimethy-
l-1H-5-pyrazolyl)methyl]-thieno[2,3-d]pyrimidine-5-carboxylic
acid
[0319] Prepared from the product of part b) by the method of
example 6 part b) to give the sub-title compound as a solid.
[0320] MS (ESI) 377 [M+H].sup.+.
d)
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-me-
thylethyl)-[(1,3-Dimethyl-1H-5-pyrazolyl)methyl]-thieno[2,3-d]pyrimidine-2-
,4-(1H,3H)-dione
[0321] Prepared from the product of part c) by the method of
example 15 part d)
[0322] MS (APCI) 462 [M+H].sup.+.
[0323] .delta. .sup.1H.sub.DMSO 1.42 (3H, s), 1.48 (6H, t), 2.08
(3H, s), 3.18 (3H, s), 3.29 (1H, m), 3.63 (3H, s), 3.74 (3H, m),
4.08 (2H, m), 4.44 (1H, bm), 5.42 (1H, s), 5.92 (1H, s).
EXAMPLE 20
6-[(3,5-Dimethyl-4-isothiozolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-isox-
azolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidine-2,4-
-(1H,3H)-dione
##STR00040##
[0324] a)
6-[(3,5-Dimethyl-4-isothiazolyl)hydroxymethyl]-1,2,3,4-tetrahydr-
o-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxyli-
c acid ethyl ester
[0325] Prepared by the method of example 15 part a) using
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrim-
idine-5-carboxylic acid ethyl ester, and
3,5-dimethyl-4-isothiazolecarboxaldehyde.
[0326] MS (ESI) 438 [M+H].sup.+.
[0327] .delta. .sup.1H.sub.DMSO 1.04 (3H, t), 1.51-1.54 (6H, m),
2.25 (3H, s), 2.42 (3H, s), 3.16 (3H, s), 3.68-3.88 (2H, m), 4.61
(1H, s, br), 6.01 (1H, d), 6.75 (1H, d).
b)
6-[(3,5-Dimethyl-4-isothiazolyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(-
1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid
ethyl ester
[0328] Prepared from the product of part a) by the method of
example 15 part b).
[0329] MS (ESI) 422 [M+H].sup.+
[0330] .delta. .sup.1H.sub.DMSO 1.25 (3H, t), 1.45 (6H, d), 2.29
(3H, s), 2.46 (3H, s), 3.17 (3H, s), 4.07 (2H, s), 4.21 (2H, q),
4.40 (1H, s, br).
c)
6-[(3,5-Dimethyl-4-isothiazolyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(-
1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid
[0331] A solution of the product of step b) (0.26 g) in
acetonitrile (10 ml) and 2.5N hydrochloric acid (10 ml) was heated
under reflux for 6 hours. It was concentrated in vacuo, diluted
with water and extracted into dichloromethane, the organic extracts
washed with water, dried over anhydrous magnesium sulfate, filtered
and evaporated under reduced pressure to afford the subtitle
compound.
[0332] MS (ESI) 394 [M+H].sup.+.
d)
6-[(3,5-Dimethyl-4-isothiozolyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-i-
soxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidine--
2,4-(1H,3H)-dione
[0333] Prepared from the product of part c) by the method of
example 10 part b).
[0334] MS (APCI) 479 [M+H].sup.+.
[0335] .delta. .sup.1H.sub.DMSO 1.31-1.46 (9H, m), 2.30-2.32 (3H,
m), 2.47-2.48 (3H, m), 3.17-3.18 (3H, m), 3.42-4.02 (6H, m), 4.36
(1H, s, br), 5.41 (1H, d).
EXAMPLE 21
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methy-
lethyl)-6-[[1-(2-thiazolyl)-1H-pyrazol-4-yl]methyl]thieno[2,3-d]pyrimidine-
-2,4-(1H,3H)-dione
##STR00041##
[0336] a) 1-(Diphenylmethyl)-1H-pyrazole-4-carboxylic acid ethyl
ester
[0337] A suspension of 1H-pyrazole-4-carboxylic acid ethyl ester
(1.0 g), benzhydryl chloride (1.9 ml) and potassium carbonate (1.48
g) in anhydrous 1-methyl-2-pyrrolidinone (10 ml) was heated at
100.degree. C. under nitrogen for 6 hours. It was diluted with
water and extracted with ethyl acetate, the organic extracts washed
with water, dried over anhydrous magnesium sulfate, filtered and
evaporated under reduced pressure. The residue was purified by
column chromatography over silica, eluting with i-hexane/ethyl
acetate (4:1) followed by i-hexane/ethyl acetate (2:1) to give the
sub-title compound (2.18 g).
[0338] .delta. .sup.1H.sub.CDCl3 1.32 (3H, t), 4.27 (2H, q), 6.77
(1H, s), 7.10-7.12 (4H, m), 7.32-7.40 (10H, m), 7.74 (1H, s), 7.99
(1H, s).
b) 1-(Diphenylmethyl)-1H-pyrazole-4-carboxaldehyde
[0339] To a solution of the product of part a) (2.18 g) in
anhydrous THF (40 ml) was added 1.1 M alumium hydride solution in
THF (10 ml) dropwise at 0.degree. C. under nitrogen and the
resulting mixture stirred at room temperature for 2 hours. It was
carefully poured into water, mixed with ethyl acetate and filtered.
It was extracted with ethyl acetate, the organic extracts washed
with water, dried over anhydrous magnesium sulfate, filtered and
evaporated under reduced pressure. The residue was dissolved in
acetone (6 ml) and the solution cooled to 10.degree. C. then
treated with chromium trioxide solution (0.66 g) in water (4 ml)
and sulphuric acid (0.53 ml), stirred at room temperature for 2
hours, and extracted with ethyl acetate, the organic extracts
washed with water, dried over anhydrous magnesium sulfate, filtered
and evaporated under reduced pressure. The residue was purified by
column chromatography over silica, eluting with i-hexane/ethyl
acetate (9:1) followed by i-hexane/ethyl acetate (3:1) to give the
sub-title compound (1.2 g).
[0340] .delta. .sup.1H.sub.DMSO 7.05 (1H, s), 7.19-7.22 (4H, m),
7.32-7.42 (6H, m), 8.08 (1H, s), 9.81 (1H, s).
c)
6-[[1-(Diphenylmethyl)-1H-pyrazol-4-yl]hydroxymethyl]-1,2,3,4-tetrahydr-
o-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxyli-
c acid ethyl ester
[0341] Prepared from the product of part b) and
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrim-
idine-5-carboxylic acid ethyl ester by the method of example 15
part a).
[0342] MS (ESI) 559 [M+H].sup.+.
d)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-(1H-pyrazol-4-
-ylmethyl)thieno[2,3-d]pyrimidine-5-carboxylic acid, ethyl
ester
[0343] Prepared from the product of part c) by the method of
example 15 part b).
[0344] MS (ESI) 377 [M+H].sup.+.
[0345] .delta. .sup.1H.sub.DMSO 1.28 (3H, t), 1.46 (6H, d), 3.19
(3H, s), 3.96 (2H, s), 4.30 (2H, q), 4.48 (1H, s, br), 7.51 (2H,
s).
e)
1,2,3,4-Tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[[1-(2-thiazo-
lyl)-1H-pyrazol-4-ylmethyl]thieno[2,3-d]pyrimidine-5-carboxylic
acid
[0346] To a solution of the product of step d) (500 mg) in
acetonitrile (2 ml) was added 2-bromothiazole (0.24 ml). The
mixture was then microwave irradiated at 200 W and 140.degree. C.
for 20 minutes. It was cooled, diluted with acetonitrile (5 ml),
2.5 N HCl (5 ml) added and the mixture heated under reflux for 18
hours. It was cooled, the precipitated solid collected by
filtration and recrystallised from DMF to give the sub-title
compound (0.1 g).
[0347] MS (ESI) 432 [M+H].sup.+.
f)
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-me-
thylethyl)-6-[[1-(2-thiazolyl)-1H-pyrazol-4-yl]methyl]thieno[2,3-d]pyrimid-
ine-2,4-(1H,3H)-dione
[0348] Prepared from the product of part e) by the method of
example 10 part b).
[0349] MS (APCI) 517 [M+H].sup.+.
[0350] .delta. .sup.1H.sub.DMSO 1.31-1.48 (9H, m), 3.19-3.20 (3H,
m), 3.36-4.06 (6H, m), 4.48 (1H, s, br), 5.43-5.46 (1H, m), 7.52
(1H, d), 7.63 (1H, d), 7.74-7.80 (1H, m), 8.37-8.44 (1H, m).
EXAMPLE 22
6-[(4-Fluorophenyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]ca-
rbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dion-
e
##STR00042##
[0351] a)
6-[(4-Fluorophenyl)hydroxymethyl]-1,2,3,4-tetrahydro-3-methyl-1--
(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid
ethyl ester
[0352] Prepared by the method of example 15 part a) using
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrim-
idine-5-carboxylic acid ethyl ester and 4-fluorobenzaldehyde.
[0353] MS (ESI) 421 [M+H].sup.+.
b)
6-[(4-Fluorophenyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl-
)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid, ethyl
ester
[0354] Prepared from the product of part a) by the method of
example 15 part b).
[0355] MS (ESI) 405 [M+H].sup.+.
[0356] .delta. .sup.1H.sub.DMSO 1.18 (3H, t), 1.45 (6H, d), 3.18
(3H, s), 4.10 (2H, s), 4.28 (2H, q), 4.43 (1H, s, br), 7.15-7.19
(2H, m), 7.29-7.33 (2H, m).
c)
6-[(4-Fluorophenyl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl-
)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid
[0357] Prepared from the product of part b) by the method of
example 20 part c).
[0358] MS (ESI) 377 [M+H].sup.+.
d)
6-[(4-Fluorophenyl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl-
]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimidine-2,4-(1H,3H)-d-
ione
[0359] Prepared from the product of part c) by the method of
example 10 part b).
[0360] MS (APCI) 462 [M+H].sup.+.
[0361] .delta. .sup.1H.sub.DMSO 1.23-1.26 (9H, m), 3.19-3.24 (3H,
m), 3.56-4.10 (6H, m), 4.45 (1H, s, br), 5.43 (1H, s), 7.15 (2H,
t), 7.30-7.37 (2H, m).
EXAMPLE 23
5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methy-
lethyl)-6-(1H-1,2,3-triazol-1-ylmethyl)thienol2,3-d]pyrimidine-2,4-(1H,3H)-
-dione
##STR00043##
[0362] a)
6-(Azidomethyl)-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,-
4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid methyl ester
[0363] To a solution of
6-(bromomethyl)-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxoth-
ieno[2,3-d]pyrimidine-5-carboxylic acid methyl ester (0.5 g) in
acetonitrile (4 ml) was added a solution of sodium azide (0.95 g)
in acetonitrile (1 ml) and water (0.5 ml) and the resulting mixture
stirred at room temperature under nitrogen for 18 hours. It was
diluted with water and extracted into ethyl acetate, the organic
extracts washed with water, dried over anhydrous magnesium sulfate,
filtered and evaporated under reduced pressure to give the
sub-title compound as a solid (0.39 g).
[0364] MS (ESI) 338 [M+H].sup.+.
[0365] .delta. .sup.1H.sub.CDCl3 1.63 (6H, d), 3.38 (3H, s), 3.98
(3H, s), 4.54 (2H, s), 4.68 (1H, s, br).
b)
6-[(4,5-Dimethyl-1H-1,2,3-triazol-1-yl)methyl]-1,2,3,4-tetrahydro-3-met-
hyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid, methyl ester
[0366] A mixture of the product of part a) (0.39 g), phenyl vinyl
sulphoxide (1.0 g) and chlorobenzene (10 ml) was heated at
130.degree. C. for 8 hours. It was cooled and concentrated in
vacuo. The residue was purified by column chromatography over
silica, eluting with i-hexane/ethyl acetate (4:1) followed by
i-hexane/ethyl acetate (1:1) to give the sub-title compound (0.39
g).
[0367] MS (ESI) 364 [M+H].sup.+.
[0368] .delta. .sup.1H.sub.DMSO 1.48 (6H, d), 3.18 (3H, s), 3.86
(3H, s), 4.51 (1H, s, br), 5.82 (2H, s), 7.76 (1H, s), 8.13 (1H,
s).
c)
6-[(4,5-Dimethyl-1H-1,2,3-triazol-1-yl)methyl]-1,2,3,4-tetrahydro-3-met-
hyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid
[0369] Prepared from the product of part b) by the method of
example 20 part c).
[0370] MS (ESI) 350 [M+H].sup.+.
d)
5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-me-
thylethyl)-6-(1H-1,2,3-triazol-1-ylmethyl)thieno[2,3-d]pyrimidine-2,4-(1H,-
3H)-dione
[0371] Prepared from the product of part c) by the method of
example 10 part b).
[0372] MS (APCI) 435 [M+H].sup.+.
[0373] .delta. .sup.1H.sub.DMSO 1.23-1.49 (9H, m), 3.18-3.19 (3H,
m), 3.37-3.99 (4H, m), 4.49 (1H, s, br), 5.43-5.52 (1H, m),
5.70-5.81 (2H, m), 7.76 (1H, s), 8.07-8.18 (1H, m).
EXAMPLE 24
6-1(6-Chloroimidazo[1,2-a]pyridin-3-yl)methyl]-5-[[(4S)-4-hydroxy-4-methyl-
-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyrimid-
ine-2,4-(1H,3H)-dione
##STR00044##
[0374] a)
6-[(6-Chloroimidazo[1,2-a]pyridin-3-yl)hydroxymethyl]-1,2,3,4-te-
trahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-ca-
rboxylic acid ethyl ester
[0375] Prepared from
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrim-
idine-5-carboxylic acid, ethyl ester and
6-chloroimidazo[1,2-a]pyridine-3-carboxaldehyde by the method of
example 15 part a).
[0376] MS (ESI) 477 and 479 [M+H].sup.+.
[0377] .delta. .sup.1H.sub.DMSO 1.02 (3H, t), 1.52 (6H, dd),
3.91-3.99 (2H, m), 4.58 (1H, s, br), 6.49 (1H, d), 7.09 (1H, d),
7.36 (1H, dd), 7.48 (1H, s), 7.67 (1H, d), 8.55 (1H, s).
b)
6-[(6-Chloroimidazo[1,2-a]pyridin-3-yl)methyl]-1,2,3,4-tetrahydro-3-met-
hyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid, ethyl ester
[0378] Prepared from the product of part a) by the method of
example 15 part b).
[0379] MS (ESI) 461 and 463 [M+H].sup.+.
[0380] .delta. .sup.1H.sub.DMSO 1.18 (3H, t), 1.44 (6H, d), 3.18
(3H, s), 4.26 (2H, q), 4.43 (1H, s, br), 4.54 (3H, s), 7.32 (1H,
dd), 7.56 (1H, s), 7.65 (1H, d), 8.57 (1H, s).
c)
6-[(6-Chloroimidazo[1,2-a]pyridin-3-yl)methyl]-1,2,3,4-tetrahydro-3-met-
hyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid
[0381] Prepared from the product of part b) by the method of
example 20 part c).
[0382] MS (ESI) 433 and 435 [M+H].sup.+.
d)
6-[(6-Chloroimidazo[1,2-a]pyridin-3-yl)methyl]-5-[[(4S)-4-hydroxy-4-met-
hyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)thieno[2,3-d]pyri-
midine-2,4-(1H,3H)-dione
[0383] Prepared from the product of part c) by the method of
example 10 part b).
[0384] MS (APCI) 518 and 520 [M+H].sup.+.
[0385] .delta. .sup.1H.sub.DMSO 1.32-1.44 (9H, m), 3.18-3.19 (3H,
m), 3.64-3.83 (4H, m), 4.35-4.53 (3H, m), 5.45-5.46 (1H, m), 7.30
(1H, dd), 7.59-7.65 (2H, m), 8.64-8.71 (1H, m).
EXAMPLE 25
5-[[(4S)-4-hydroxy-4-methylisoxazolidin-2-yl]carbonyl]-3-methyl-1-(1-methy-
lethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-thieno[2,3-d]pyrimidine-2,4(1H,3-
H)-dione
##STR00045##
[0386] a)
1,2,3,4-Tetrahydro-6-[hydroxy[4-(2-pyridinyl)phenyl]methyl]-3-me-
thyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic
acid, ethyl ester
[0387] Lithium diisopropylamide, freshly made by adding
n-buthyllithium (1.1 mL, 2.5 M in hexanes) to a solution of
diisopropylamine (0.46 mL) in dry tetrahydrofuran under nitrogen at
0.degree. C. and stirring for 20 minutes, was added to a solution
of
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thieno[2,3-d]pyri-
midine-5-carboxylic acid, ethyl ester (0.7 g),
4-(2-pyridyl)benzaldehyde (0.52 g) and DMPU (057 mL) in dry
tetrahydrofuran under nitrogen at -78.degree. C. The reaction
mixture was stirred at -78.degree. C. for 4 hours then quenched
with glacial acetic acid (10 mL) and allowed to reach room
temperature. Water was added and the mixture was extracted with
ethyl acetate (twice). The organics were washed with brine, dried
over MgSO.sub.4 and concentrated under vacuum to give a brown oil
which was purified by silica chromatography eluting with
isohexane/ethyl acetate (1/1) to give the sub-title compound as a
pale yellow foam (0.47 g).
[0388] MS (ES) 480 [M+H].sup.+.
[0389] .delta. .sup.1H.sub.DMSO 1.15-1.23 (3H, t), 1.47-1.53 (6H,
d), 3.17 (3H, s), 4.16-4.24 (2H, q), 4.55 (1H, bs), 5.97-5.98 (1H,
d), 6.82-6.84 (1H, d), 7.32-7.37 (1H, m), 7.47-7.50 (2H, d),
7.84-7.96 (2H, m), 8.05-8.08 (2H, d), 8.64-8.66 (1H,d).
b)
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[[4-(2-pyridi-
nyl)phenyl]methyl]-thieno[2,3-d]pyrimidine-5-carboxylic acid, ethyl
ester
[0390] The product of part a) (0.47 g) dissolved in dichloromethane
(2 mL) was treated with trifluoroacetic acid (2 mL) and
triethylsilane (1 mL) and stirred at ambient temperature for 18
hours. Dichloromethane and trifluoroacetic acid were evaporated.
Water was added and the reaction mixture was basified with sodium
carbonate then extracted with dichloromethane (twice). The organics
were washed with brine, dried over MgSO.sub.4 and concentrated
under vacuum to give a white solid which was purified by silica
chromatography eluting with isohexane/ethylacetate (3/2) to give
the sub-title compound as a colourless oil which solidified (0.39
g).
[0391] MS (ES) 464 [M+H].sup.+.
[0392] .delta. .sup.1H.sub.DMSO 1.23-1.28 (3H, t), 1.44-1.46 (6H,
d), 3.18 (3H, s), 4.16 (2H, s), 4.27-4.31 (2H, q), 4.33 (1H, bs),
7.32-7.36 (1H, m), 7.36-7.38 (2H, d), 7.85-7.89 (1H, t), 7.93-7.95
(1H, d), 8.04-8.06 (2H, d), 8.64-8.66 (1H, d).
c)
1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-6-[[4-(2-pyridi-
nyl)phenyl]methyl]-thieno[2,3-d]pyrimidine-5-carboxylic acid
[0393] Prepared from a solution of the product of part b) (0.39 g)
in acetonitrile (15 mL) which was treated with 2 M hydrochloric
acid (4 mL) and heated at reflux for 15 hours. The mixture was
concentrated to dryness. The residue was triturated with water,
filtered and washed with ether then dried in a vacuum oven at
55.degree. C. to give the sub-title compound as a white solid (0.22
g).
[0394] MS (ES) 436 [M+H].sup.+.
d)
5-[[(4S)-4-Hydroxy-4-methylisoxazolidin-2-yl]carbonyl]-3-methyl-1-(1-me-
thylethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-thieno[2,3-d]pyrimidine-2,4(1-
H,3H)-dione
[0395] To a solution of the product of part c) (0.22 g) in
dichloromethane was added oxalyl chloride (0.132 mL) followed by 2
drops of dimethylformamide under nitrogen. The reaction mixture was
stirred at ambient temperature for 1 hour then concentrated to
dryness. The residue was dissolved in dichloromethane then added to
a solution of (4S)-4-hydroxy-4-methylisoxazolidine hydrochloride
(0.14 g) and triethylamine (0.3 mL) in dichloromethane. The
reaction mixture was stirred at room temperature for 2 hours. Water
was added. The reaction mixture was partitionned and the organics
were dried over MgSO.sub.4 then concentrated under vacuum. The
residue was purified by silica chromatography eluting with 4%
methanol in dichloromethane then again with ethyl acetate. Finally,
another purification by reverse phase HPLC eluting with
acetonitrile/0.2% NH.sub.3 in water was carried out to give the
title compound as a white solid (0.1 g).
[0396] MS (APCI) 521.1860 [M+H].sup.+.
[0397] .delta. .sup.1H.sub.CDCl3 1.52-1.56 (9H, m), 3.35 (3H, s),
3.42-3.46 (1H, d), 3.86-4.01 (2H, ABq), 4.18 (2H, s), 4.52-4.56
(2H, d+bs), 5.42 (1H, s), 7.21-7.24 (1H, m), 7.34-7.42 (2H, d),
7.69-7.78 (2H. m), 7.78-7.94 (2H, d), 8.67-8.69 (1H, d).
EXAMPLE 26
(4S)-4-Methyl-2-[[1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-6-[[5-meth-
yl-1-(2-pyrimidinyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,4-dioxo-
thieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-isoxazolidinol
##STR00046##
[0399] A mixture of the product of example 10 part b) (279 mg),
2-bromopyrimidine (300 mg), copper(I) iodide (95 mg),
trans-cyclohexanediamine (55 mg) and potassium carbonate (300 mg)
in dioxane (2 ml) was heated at 100.degree. C. for 16 hours under
nitrogen.
[0400] The reaction mixture was concentrated to dryness and
purified by silica chromatography eluting with an ethyl acetate to
10% methanol/ethyl acetate gradient, followed by RPHPLC to give the
title compound as a white solid (105 mg).
[0401] MS (APCI+ve) 494 [M+H].sup.+.
[0402] .delta. .sup.1H.sub.DMSO, 120.degree. C. 1.40 (3H, s), 1.47
(6H, d), 2.53 (3H, s), 3.21 (3H, s), 3.64-3.72 (3H, m), 3.80 (1H,
d), 4.07 (2H, s), 4.46 (sep, 1H), 7.59 (1H, t), 8.94 (2H, d).
EXAMPLE 27
(4S)-2-[[6-[[3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,-
4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothienol[2,3-d]pyrimidin-5-
-yl]carbonyl]-4-ethyl-4-isoxazolidinol
##STR00047##
[0403] a) (S)-([2-Ethyloxiranyl]methyl)
3-nitro-benzenesulfonate
[0404] A mixture of 2-ethylprop-2-en-1-ol (1.5 g), powdered 3
A.degree. molecular sieves (620 mg) and (-)-D-diethyltartrate (177
Bu) was stirred in dichloromethane (35 ml) under nitrogen for 24
hours. The mixture was cooled to -20.degree. C. and titanium
tetraisopropoxide (265 .mu.l) was added. After stirring for 2 hours
at -20.degree. C. cumene hydroperoxide (6.4 ml) was added and after
a further 2 hours the reaction allowed to warm to -5.degree. C.
before being quenched by the slow addition of trimethylphosphite
(3.4 ml).
[0405] Triethylamine (3.7 ml), DMAP (265 mg) and a solution of
3-nitrobenzene-sulphonyl chloride (3.95 g) in dichloromethane (25
ml) were then added sequentially and the mixture stirred at room
temperature for 3 hours. The reaction mixture was poured onto
silica and eluted with dichloromethane to give the sub-title
compound as a yellow oil (4.8 g).
[0406] .delta. .sup.1H.sub.CDCl3 0.91 (3H, t), 1.61 (1H, sex), 1.81
(1H, sex), 2.68 (1H, d), 2.70 (1H, d), 4.09 (1H, d), 4.31 (1H, d),
7.81 (1H, t), 8.25 (1H, ddd), 8.53 (1H, ddd), 8.77 (1H, t).
b) 2-[[(2S)-2-Ethyloxiranyl]methoxy]-1H-isoindole-1,3(2H)-dione
[0407] The sub-title compound was prepared using the method of
example 1 part a) using the product of part a).
[0408] .delta. .sup.1H.sub.CDCl3 1.04 (3H, t), 1.89 (1H, dq), 2.11
(1H, dq), 2.72 (1H, d), 2.75 (1H, d), 4.22 (1H, d), 4.25 (1H, d),
7.72-7.77 (2H, m), 7.82-7.87 (2H, m).
c)
2-[[(2R)-3-Chloro-2-hydroxy-2-ethylpropyl]oxy]-1H-isoindole-1,3(2H)-dio-
ne
[0409] The sub-title compound was prepared using the method of
example 1 part b) using the product of part b).
[0410] .delta. .sup.1H.sub.CDCl3 1.01 (3H, t), 1.71 (1H, dq), 1.75
(1H, dq), 3.70 (1H, d), 3.75 (1H, d), 4.08 (1H, d), 4.50 (1H, d),
7.75-7.80 (2H, m), 7.84-7.88 (2H, m).
d) 2-[[(4S)-4-Hydroxy-4-ethyl-2-isoxazolidinyl]carbonyl]-benzoic
acid, methyl ester
[0411] The sub-title compound was prepared using the method of
example 1 part c) using the product of part c).
[0412] .delta. .sup.1H.sub.CDCl3 1.09 (3H, t), 1.82 (2H, q), 2.01
(1H, s), 3.59 (1H, d), 3.84 (1H, d), 3.92 (3H, s), 3.94 (1H, d),
4.32 (1H, d), 7.45 (1H, d), 7.49 (1H, t), 7.62 (1H, t), 7.99 (1H,
d).
[0413] HPLC: (9010IHIP.M) 4.6.times.250 mm kromasil DMB column,
ee>99%.
e) (4S)-4-Ethyl-4-isoxazolidinol hydrochloride
[0414] The sub-title compound was prepared using the method of
example 1 part d) using the product of part d).
[0415] .delta. .sup.1H.sub.DMSO 0.94 (3H, t), 1.66-1.79 (2H, M),
3.28 (1H, d), 3.38 (1H, d), 3.90 (1H, d), 4.05 (1H, d).
f)
(4S)-2-[[6-[[3,5-Dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2-
,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-
-5-yl]carbonyl]-4-ethyl-4-isoxazolidinol
[0416] The title compound was prepared from the product of example
11 part b) using the method of example 15 part d).
[0417] MS (APCI+ve) 554 [M+H].sup.+.
[0418] .delta. .sup.1H.sub.DMSO, 120.degree. C. 0.94 (3H, t), 1.47
(6H, d), 1.71 (2H, q), 2.18 (3H, s), 2.52 (3H, s), 3.20 (3H, s),
3.64 (1H, m), 3.74-3.8 (3H, m), 3.89 (2H, s), 4.46 (sep, 1H), 7.38
(1H, t), 8.81 (2H, d)
EXAMPLE 28
(4s)-2-[[6-[[1-(2,3-dihydro-2-oxo-4-pyrimidinyl)-3,5-dimethyl-1H-pyrazol-4-
-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[-
2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxazolidinol
##STR00048##
[0419] a)
6-[[1-(2,3-Dihydro-2-oxo-4-pyrimidinyl)-3,5-dimethyl-1H-pyrazol--
4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-thien-
o[2,3-d]pyrimidine-5-carboxylic acid
[0420] A mixture of the product of example 2 part b) (400 mg),
2,4-dichloropyrimidine (160 mg) and triethylamine (310 .mu.l) in
acetonitrile (50 ml) was heated at reflux for 2 hours. The mixture
was washed with water and the organics concentrated to dryness to
give the sub-title compound as a brown oil (150 mg).
[0421] .delta. .sup.1H.sub.DMSO 1.45 (6H, d), 2.18 (3H, s), 2.57
(3H, s), 3.22 (3H, s), 4.12 (2H, s), 4.35 (s, 1H), 5.44 (1H, d),
7.34-7.41 (1H, m).
b)
(4s)-2-[[6-[[1-(2,3-Dihydro-2-oxo-4-pyrimidinyl)-3,5-dimethyl-1h-pyrazo-
l-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothie-
no[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-4-isoxazolidinol
[0422] The title compound was prepared from the product of part a)
using the method of example 15 part d).
[0423] MS (APCI+ve) 556 [M+H].sup.+.
[0424] .delta. .sup.1H.sub.DMSO 120.degree. C. 1.40 (3H, s), 1.47
(6H, d), 2.17 (3H, s), 2.54 (3H, s), 3.20 (3H, s), 3.66-3.80 (4H,
m), 3.88 (2H, s), 4.46 (sep, 1H), 6.13 (1H, d), 7.87 (2H, d).
EXAMPLE 29
5-[[(4R)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methy-
lethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,-
3-d]pyrimidine-2,4(1H,3H)-dione
##STR00049##
[0425]
5-[[(4R)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(-
1-methylethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-th-
ieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
[0426] To a suspension of the product of example 10 part a) (0.130
mg) and (4R)-4-methyl-4-isoxazolidinol hydrochloride (42 mg,
prepared by the method of example 1 steps a) to d) using
[(2R)-2-methyloxiran-2-yl]methyl 3-nitrobenzenesulfonate) in
anhydrous THF (6 ml), was added triethylamine (120 mg) and the
mixture was cooled in an icebath.
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (120 mg) was added and the mixture was allowed
to warm to, whereupon it was stirred for 3 hours. All volatiles
were removed in vacuo and the residue was chromatographed
(SiO.sub.2/1:1 CH.sub.2Cl.sub.2-EtOAc) to effect primary
purification. Further purification by RPHPLC afforded the title
compound as a solid (35 mg).
[0427] MS (ESI) 516 [M+H].sup.+.
[0428] .delta. .sup.1H.sub.DMSO (120.degree. C.) 1.40 (3H, s), 1.46
(6H, d), 2.18 (3H, s), 3.20 (3H, s), 3.6-3.75 (3H, br s+d), 3.81
(1H, d), 3.94 (2H, s), 4.5 (1H, m), 4.95-5.05 (1H, br s).
[0429] CHN: Found C: 47.98%; H: 4.69%; N: 13.48%; S: 5.98%.
[0430] C.sub.21H.sub.24F.sub.3N.sub.5O.sub.5.0.5H.sub.2O requires
C: 48.09%; H: 4.8%; N: 13.35%; S: 6.11%.
Pharmacological Data
Inhibition of PMA/Ionomycin-Stimulated Peripheral Blood Mononuclear
Cell Proliferation
[0431] The assay for PMA/ionomycin-stimulated PBMC proliferation
was performed in 96-well flat-bottomed microtitre plates. Compounds
were prepared as 10 mM stock solutions in dimethyl sulfoxide. A
50-fold dilution of this was prepared in RPMI and serial dilutions
were prepared from this solution. 10 .mu.l of the 50-fold diluted
stock, or dilutions of it, were added to the well to give
concentrations in the assay starting at 9.5 .mu.M and going down.
Into each well was placed 1.times.10.sup.5 PBMC, prepared from
human peripheral blood from a single donor, in RPMI1640 medium
supplemented with 10% human serum, 2 mM glutamine and
penicillin/streptomycin. Phorbol myristate acetate (PMA) (0.5 ng/ml
final concentration) and ionomycin (500 ng/ml final concentration)
were added to these cells in supplemented RPMI1640 medium (as
above) so that the final volume of the assay was 0.2 ml. The cells
were incubated at 37.degree. C. in a humidified atmosphere at 5%
carbon dioxide for 72 hours. .sup.3H-Thymidine (0.5 .mu.Ci) was
added for the final 6 hours of the incubation. The level of
radioactivity incorporated by the cells was then determined and
this is a measure of proliferation.
[0432] The compounds of the Examples were found to exhibit an
IA.sub.50 value of less than 1.times.10.sup.-6 M in the above test.
In the following specific examples, Examples 5, 7 and 8 had a
PIA.sub.50 of 7.4, 8.6 and 9.0 respectively in the above test.
* * * * *